IGFBP2 in cell culture

By detecting the level of IGFBP2 in the culture medium, this method addresses the shortcomings of traditional cell counting methods in terms of accuracy and real-time performance in large-scale cell culture systems. It provides a non-invasive and rapid method for assessing cell number and status, thereby improving the efficiency and cost-effectiveness of cell culture.

CN123076786APending Publication Date: 2026-11-10BLUEROCK THERAPEUTICS LP
View PDF 24 Cites 0 Cited by

Patent Information

Application Number
CN202580021777.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-01-31
Filing Date
2025-01-30
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing cell counting methods struggle to accurately estimate cell numbers without damaging the cells, especially in large-scale cell culture systems. Traditional methods are prone to human error, and expensive automated systems may not be able to account for cell clumping or uneven distribution, nor can they provide real-time data.

Method used

Using IGFBP2 concentration as a biomarker for cell counting and health assessment, this method provides a non-invasive approach suitable for cell monitoring under various culture conditions by detecting IGFBP2 levels in the culture medium to estimate cell number and assess cell status.

Benefits of technology

It enables rapid and accurate estimation of cell number and assessment of cell status without damaging cells, simplifies the cell culture process, improves cost-effectiveness and production efficiency, reduces labor-intensive operations, and provides real-time monitoring of cell health and culture conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123076786A_ABST
    Figure CN123076786A_ABST
Patent Text Reader

Abstract

The present disclosure relates to methods for detecting IGFBP2 concentration in cell cultures and applications thereof, such as for estimating the number of cells in a culture, assessing the health of cells in a culture, normalizing data from different experiments, and assessing production of secreted molecules.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-referencing of related patent applications This application claims priority to U.S. Provisional Application No. 63 / 627,359, filed January 31, 2024, the contents of which are incorporated herein by reference in their entirety.

[0002] sequence list This application includes a sequence list submitted electronically in XML format, the entire sequence list of which is incorporated herein by reference. The XML sequence list was created on December 12, 2024, and is named BRT-009WO_SL.xml, with a file size of 361,501 bytes. Background Technology

[0003] Obtaining accurate estimates of cell numbers in cell culture systems is crucial for monitoring cell proliferation and viability, optimizing cell culture conditions, preparing cell-based assays, and processing cells for downstream use.

[0004] There are various methods for counting cultured cells, ranging from manual counting using a microscope to counting cells using automated cell counters or flow cytometry. However, existing cell counting methods have several drawbacks. Manual cell counting relies on human visualization, which is prone to inaccuracies due to subjective differences, selection of culture dish areas that do not represent the entire culture vessel, or inappropriate visualization of samples associated with cell aggregation, debris, or visual problems. Automated cell counting techniques can eliminate subjective errors; however, they may require treating cells with dyes or separating cells to produce a homogenized cell suspension, both of which not only disrupt the cells in the culture but also introduce errors due to aggregation and debris.

[0005] There is a need in the art for a reliable method to estimate cell numbers without damaging the cells in the culture system. Summary of the Invention

[0006] This disclosure relates to the use of the concentration of secreted IGFBP2 in the culture medium for cell culture as a measure of cell counting, cell health, and cell product level standardization. Using secreted IGFBP2 levels as an alternative for cell counting, cell health, and cell product level standardization is particularly useful in cultures involving cells attached to specific surfaces, such as in roller flasks, tissue culture plates, or cell factories.

[0007] Therefore, this disclosure provides a method for quantifying (e.g., detecting its concentration) IGFBP2 in cell culture media (for convenience, it is sometimes referred to herein as "IGFBP2 assay"), and its application in many laboratory, research and clinical applications.

[0008] Methods for quantifying IGFBP2 levels in culture medium samples are described in Section 6.3 and in embodiments numbered 1 to 43, comprising the methods and reagents described in Section 6.3.1 and embodiments numbered 33 to 35, and the times and frequencies described in Section 6.3.2 and embodiments numbered 4 to 25. IGFBP2 can be expressed as multiple splice variants, as described in Section 6.2. The methods of this disclosure can detect any single splice variant or a combination of splice variants (or all splice variants).

[0009] The IGFBP2 assay of this disclosure can be used to estimate cell number and / or detect abnormalities in cell cultures of various cell types (e.g., by indicating abnormal proliferation, for example, in cell cultures containing cells that have undergone maturation), as described in Section 6.4 and numbered embodiments 44 to 95. In some embodiments, the cells are pluripotent stem cells (PSCs), as described in Section 6.4.1, including but not limited to induced pluripotent stem cells (iPSCs), and PSC-derived cells, as described in Section 6.4.2.

[0010] Further applications of the IGFBP2 assay of this disclosure include the standardization of cell product levels, as described in Section 6.5.4 and numbered embodiments 96 to 104, and the assessment of cell health, as described in Section 6.5.5 and numbered embodiments 105 to 142. Attached Figure Description

[0011] Figure 1 This is a schematic diagram of an exemplary workflow relating to an IGFBP2 assay applied to PSCs. The core of method (5) requires the detection of IGFBP2 levels in the cell culture medium (white arrows with solid borders), typically (but not necessarily) prior to feeding the cell culture (dashed arrows with solid borders). This process can be repeated once or multiple times (white and dotted arrows with dashed borders). Prior to the core of the workflow (5) may be optional steps such as: seeding PSC cell cultures (4), optionally after the generation of PSCs (1), thawing and / or passage of PSCs (2) and / or passage of PSCs (3). After the core of the workflow (5) may be passage of PSCs (6), differentiation of PSCs (7), preservation of PSCs (8) (e.g., by cryopreservation), disposal of PSCs (9), or any combination thereof. Optional steps in this process are indicated by dashed lines. Although shown as applied to PSCs, the IGFBP2 assay of this disclosure can be used for other cell types, including but not limited to cell types differentiated from or undergoing differentiation from PSCs. In some implementations, the IGFBP2 assay can be applied to cell cultures in which PSCs are differentiating into dopaminergic (DA) neurons.

[0012] Figure 2A and2B This is a graph showing the correlation between IGFBP2 concentration and cell density detected in the culture medium. Figure 2A The study showed a linear correlation between IGFBP2 expression and iPSC seeding density. Figure 2B The concentration of IGFBP2 and the number of PCS detected in the culture medium are shown.

[0013] Figures 3A-3C This is a graph showing the correlation between the concentration of IGFBP2 detected in the culture medium and the cell counting method. Figure 3A The linearity between PSC inoculation density and IGFBP2 levels was shown in three experimental groups (d1, d2, and d3). Supernatant samples were collected at 24 and 48 hours after inoculation with cultures used for d1 and d2 assays, respectively, and at 24 hours after culture medium replacement and 72 hours after inoculation with a separate culture used for d3 assays. Figure 3B The correlation between IGFBP2 levels on days 1, 2, and 3 and Incucyte®-based cell counting assays was shown. Figure 3C The study showed differences in IGFBP2 correlation between Incucyte®-based and NC200-based cell counts in day 3.

[0014] Figures 4A-4B The correlation between IGFBP2 levels and iPSC cell counts was shown in four cell factories. One cell factory was harvested daily between days 1 and 4 for data collection. Figure 4A It is a graph showing the IGFBP2 level and cell count for each group. Figure 4B Display in tabular form and Figure 4A Same information.

[0015] Figures 5A-5B The levels of IL12 in individual PSC clones are shown as normalized by cell number detection via NC200 or IGFBP2 levels. Figure 5A The IL12 level was shown as normalized by cell number. Figure 5B Shown in Figure 5A The IL12 levels in the same group of samples are normalized by IGFBP2 levels.

[0016] Figures 6A-6B The changes in IGFBP2 levels were shown in different batches of experiments. Figure 6A The differences in IGFBP2 levels across different datasets are shown. Figure 6B The linearity of the combined dataset is shown.

[0017] Figures 7A-7BThe study showed changes in IGFBP2 levels in PSCs differentiated into dopaminergic (DA) neurons and the correlation between IGFBP2 levels and DA neuron cell yield. Figure 7A The study showed the changes in IGFBP2 levels over time in 11 different batches of DA neurons, 6 of which were differentiated from 2D and 5 from 3D PSC cultures. Figure 7B The correlation between IGFBP2 levels on day 12 (D12) and cell number yield on day 16 (D16) after differentiation was shown in five batches of DA neurons differentiated from 3DPSC cultures.

[0018] Figures 8A-8C Differences in cell counts and IGFBP2 levels were shown in relation to the coating conditions of the culture vessel. Figure 8A Differences in cell counts were shown in cultures seeded on cell factories that were coated with a substrate overnight at 4°C (standard coating treatment) or for one hour at room temperature (experimental coating treatment). CF10, 10-layer cell factory; CF1-4, cell factories 1-4 with standard coating treatment; CF5-12, cell factories 5-12 with experimental coating treatment. Figure 8B The study showed differences in IGFBP2 levels in the supernatant of cultures seeded on cell factories that were coated with the matrix overnight at 4°C or coated at room temperature for 1 hour. Figure 8C The linearity of the combined dataset is shown.

[0019] Figures 9A-9B The study showed the effect of differences in culture medium supplementation on IGFBP2 levels and spheroid formation in 3D PSC cultures. Figure 9A The study showed differences in IGFBP2 levels in PSC cultures supplemented with either Y-27632 or a CEPT mixture. Figure 9B Showing with Figure 9A Differences in spheroid counts in the same PSC culture.

[0020] Figures 10A-10B The correlation between IGFBP2 levels and the amount of cell spheroids in 3D PSC cultures was shown. Figure 10A The correlation between IGFBP2 levels and globular body count is shown. Figure 10B The correlation between IGFBP2 levels and total spheroid volume is shown.

[0021] Figure 11A-11D Differences in IGFBP2 levels and cell yield counts related to cell seeding density were shown. Figure 11A The results showed that on day 1, the concentrations were 2.5k, 5k, 10k, and 20k cells / cm³. 2Differences in IGFBP2 levels in the supernatant of inoculated clones. Figure 11B The results showed values ​​of 2.5k, 5k, 10k, and 20k cells / cm³. 2 Changes in IGFBP2 levels in the supernatant of inoculated clones over time. Figure 11C It showed that with 5k cells / cm 2 The difference in cell yield between cultures inoculated and harvested on days 3, 4, and 5 compared to the amount of IGFBP2 detected. Figure 11D IGFBP2 was shown to be effective at concentrations of 2.5 kJ, 5 kJ, 10 kJ, and 20 kJ / cm³. 2 The relationship between differences in cell count yield among inoculated clones.

[0022] Figures 12A-12H Bright-field images of PSCs inoculated at different densities 3 or 4 days post-inoculation are shown. Figure 12A The PSC was shown at 2.5 k cells / cm². 2 Cell density 3 days after inoculation. Figure 12B The PSC was shown at 5k cells / cm². 2 Cell density 3 days after inoculation. Figure 12C The PSC was shown at 10k cells / cm². 2 Cell density 3 days after inoculation. Figure 12D The PSC was shown at 20 k cells / cm². 2 Cell density 3 days after inoculation. Figure 12E The PSC was shown to be 2.5 k cells / cm². 2 Cell density 4 days after inoculation. Figure 12F PSC was shown at 5k cells / cm 2 Cell density 4 days after inoculation. Figure 12G PSC was shown at 10k cells / cm 2 Cell density 4 days after inoculation. Figure 12H The PSC was shown to be 20 k cells / cm². 2 Cell density 4 days after inoculation.

[0023] Figures 13A-13D The results show that the concentration of cells at 5 kb / cm² was assessed at 3, 4, and 5 days post-inoculation. 2 FACS analysis results of pluripotency markers in inoculated PSC clones. Figure 13A The percentage of OCT4-positive cells is shown. Figure 13B The percentage of NANOG-positive cells is shown. Figure 13C The percentage of SOX2-positive cells is shown. Figure 13D The percentage of SSEA4-positive cells is shown.

[0024] Figures 14A-14DThe results of FACS analysis of pluripotency markers in PSC clones inoculated at different densities and evaluated 4 days post-inoculation are shown. Figure 14A The percentage of OCT4-positive cells is shown. Figure 14B The percentage of NANOG-positive cells is shown. Figure 14C The percentage of SOX2-positive cells is shown. Figure 14D The percentage of SSEA4-positive cells is shown.

[0025] Figures 15A-15B The results showed initial concentrations of 2.5k, 5k, 10k, and 20k cells / cm². 2 The results of PSC re-layout after inoculation. Figure 15A The confluence of cells in the rearranged plate is shown. Figure 15B The percentage of cells recovered from the re-coated plates is shown.

[0026] Figures 16A-16H The correlation between IFPPB2 levels and various detection methods is shown. Figure 16A The study showed a correlation between IGFBP2 levels on day 1 post-vaccination and vaccination density. Figure 16B The correlation between IGFBP2 levels on day 4 post-inoculation and cell number yield on day 4 was shown. Figure 16C The data showed IGFBP2 levels on the day of harvest compared to those at 200 kcal / cm². 2 Correlation between the confluence percentage of rearranged cells. Figure 16D The data showed IGFBP2 levels on the day of harvest compared to those at 100 kcal / cm². 2 Correlation between the confluence percentage of rearranged cells. Figure 16E The correlation between IGFBP2 levels on the day of harvest and the percentage of OCT4-positive cells was shown, including all data points. Figure 16F The correlation between IGFBP2 levels on the day of harvest and the percentage of SOX2-positive cells was shown, including all data points. Figure 16G The study showed a correlation between IGFBP2 levels on the day of harvest and the percentage of OCT4-positive cells, excluding those from cells at a concentration of 20 kb / cm². 2 Data on PSC vaccinations. Figure 16H The study showed a correlation between IGFBP2 levels on the day of harvest and the percentage of SOX2-positive cells, excluding those from cells at 20 kb / cm². 2 Data on PSC vaccinations.

[0027] Figures 17A-17C The study showed the relationship between IGFBP2 levels and the maturation of cardiomyocytes cultured under different conditions. Figure 17AThe differences in IGFBP2 levels were shown in each culture. Figure 17B and Figure 17C The results of FACS analysis of cultured B cardiomyocytes are shown, wherein the cultured B cardiomyocytes were prepared using optimal ( Figure 17B ) or low ( Figure 17C A certain amount of culture medium additives were used to differentiate PSCs. Detailed Implementation

[0028] Accurately estimating cell numbers under diverse culture conditions is a significant challenge. Traditional methods for cell counting, such as manual counting under a microscope or using automated cell counters, typically require harvesting cells, which can be labor-intensive and destructive to the cell culture environment. These methods are particularly challenging in large-scale cell culture systems, such as cell factories, where visual estimation and / or obtaining representative cell samples is difficult due to the scale and complexity of the setup. Furthermore, monitoring during the culture process to ensure the maintenance of cell health and consistent cell culture (e.g., growth, differentiation, dedifferentiation, or maturation) is crucial for the preparation of cell therapies and is also useful for research and therapeutic development.

[0029] Current solutions for cell counting and monitoring in cell culture systems have several limitations. Manual counting is susceptible to human error and variability, while automated systems are expensive and may not accurately account for cell clumping or uneven distribution. Furthermore, these methods typically require cell separation and resuspension, which can affect cell viability and alter culture conditions. These challenges are amplified in large-scale systems, such as bioreactors or multilayer cell factories, making accurate and timely cell counts difficult. Moreover, existing methods may not provide real-time data on cell health or the effects of different culture conditions, thus reducing their practicality in dynamic and complex cell culture environments.

[0030] This disclosure addresses these challenges by utilizing IGFBP2 concentration as a novel biomarker for estimating cell numbers and assessing cell culture status under various culture conditions (e.g., detecting anomalies in cell cultures, such as abnormal proliferation in cell cultures containing cells undergoing maturation). By correlating IGFBP2 levels with cell counts and / or cell status, the methods of this disclosure provide a non-invasive and efficient way to monitor cell cultures without harvesting cells. This approach is particularly advantageous in large-scale and visually challenging environments, such as cell factories and 3D cultures, where conventional methods are inadequate. Furthermore, the methods of this disclosure can be applied to provide insights into the effects of different culture conditions (e.g., seeding density, substrate coating, and culture medium supplements) on cell growth and health, thereby enhancing the ability to optimize and control cell culture processes.

[0031] The methods described herein offer significant advantages over conventional cell counting methods, particularly in terms of cost and time efficiency. By utilizing IGFBP2 concentration as a marker of cell number, these methods provide rapid assessment of cell culture status during the culture process without interfering with the culture (e.g., through passage or harvesting), enabling cost-effective decisions (e.g., stopping the addition of one or more reagents to the culture to adjust culture conditions). The methods described herein can reduce or eliminate the need for labor-intensive and time-consuming manual cell counting, which often requires harvesting cells and results in cell loss or destruction. Furthermore, the ability to monitor cell status (e.g., health and / or maturity) via IGFBP2 levels allows for early detection of unhealthy or other unsuitable cultures, enabling timely intervention or termination of unsuitable cultures. This proactive management reduces unnecessary expenditures on culture media and other resources, as unlikely-to-succeed cultures can be discarded early, preventing further investment in their maintenance. Overall, the methods described herein simplify the cell culture process and provide a more efficient and cost-effective solution compared to conventional cell counting and culture monitoring techniques.

[0032] In some aspects, this disclosure provides a method for estimating the number of cells in a pluripotent stem cell culture. The method typically includes detecting the concentration of IGFBP2 in the culture supernatant. The concentration of IGFBP2 is an indicator of cell count, and therefore in some embodiments, the detected concentration may be correlated with cell count. This method provides an efficient means of estimating the number of cells in a pluripotent stem cell culture, reducing the need for destructive cell harvesting and manual counting, thereby preserving cell viability and the integrity of the culture.

[0033] In some aspects, this disclosure provides methods for assessing the health of cultured pluripotent stem cells. These methods typically include detecting the concentration of IGFBP2 in the culture supernatant. The concentration of IGFBP2 is an indicator of cell health, and therefore, in some embodiments, the detected concentration can be compared to a reference indicating healthy cells. These methods enable timely intervention to maintain optimal culture conditions by providing a reliable biomarker (IGFBP2) reflecting the physiological state of the cells, allowing for real-time assessment of stem cell health. In some embodiments, the IGFBP2 concentration is assessed within a target range, such as 150 ng / ml to 250 ng / ml or 150 ng / ml to 300 ng / ml, to assess cell health.

[0034] In some aspects, this disclosure provides methods for standardizing experimental data across multiple batches of pluripotent stem cell cultures. These methods typically involve using IGFBP2 concentration as a standardization marker to standardize results. Therefore, in some embodiments, the methods include detecting IGFBP2 concentrations across multiple batches of pluripotent stem cell cultures and adjusting the quantification of other cell cultures for the detected IGFBP2 concentration. These methods allow for the standardization of experimental data across multiple batches using IGFBP2 concentration, reducing variability and enhancing the reproducibility of results, which is crucial for consistent and reliable scientific research and applications.

[0035] In some aspects, this disclosure provides methods for evaluating the effects of cell culture conditions on the growth of pluripotent stem cells. These methods typically involve detecting the concentration of IGFBP2 in cultures subjected to different conditions (e.g., coating conditions). Therefore, in some embodiments, the methods of this disclosure include detecting the concentration of IGFBP2 under different cell culture conditions and using the detected concentrations to identify suitable or optimal cell growth conditions. These methods can be used to evaluate different cell culture conditions, such as matrix coating, thereby facilitating the optimization of the culture environment to improve cell proliferation and health.

[0036] In some aspects, this disclosure provides methods for determining the differentiation efficiency of pluripotent stem cells (e.g., differentiating into dopaminergic neurons). The methods typically include detecting the concentration of IGFBP2 in the culture supernatant during differentiation. IGFBP2 concentration is correlated with the yield of differentiated cells. Therefore, in some embodiments, the methods of this disclosure include detecting the concentration of IGFBP2 in the differentiation culture and correlating this concentration with differentiation success and / or cell yield. These methods provide quantitative detection of differentiation efficiency, such as differentiation into dopaminergic neurons, thereby enabling optimization of differentiation protocols and improvement in the yield and quality of differentiated cell type products. In some embodiments, a final target range of IGFBP2 concentration less than 500 ng / ml for dopaminergic neuron differentiation is used to assess differentiation efficiency.

[0037] In some aspects, this disclosure provides methods for determining the maturation efficiency of differentiated cells, such as cardiomyocytes, including cells differentiated from pluripotent stem cells. The methods typically include detecting the concentration of IGFBP2 in the culture supernatant during maturation. IGFBP2 concentration is correlated with the yield of mature cells. Therefore, in some embodiments, the methods of this disclosure include detecting the concentration of IGFBP2 in cell cultures undergoing maturation and correlating this concentration with the success of cell maturation and / or the yield of mature cells. The methods provide a quantitative determination of maturation efficiency (e.g., the maturation efficiency of cardiomyocytes), enabling optimization of maturation protocols and improvement in the yield and quality of mature cell type products. In some embodiments, the IGFBP2 concentration is compared to a target range (e.g., 0 ng / ml to 20 ng / ml when the culture contains cardiomyocytes) to assess maturation efficiency.

[0038] In some aspects, this disclosure provides methods for optimizing pluripotent stem cell culture conditions. These methods typically involve detecting IGFBP2 concentrations in cultures supplemented with different culture medium components. IGFBP2 concentration is associated with cell growth and health. Therefore, in some embodiments, the methods of this disclosure include detecting IGFBP2 in cultures supplemented with different culture medium components and identifying culture medium components suitable for cell growth and / or cell health. These methods help optimize culture conditions by correlating IGFBP2 concentration with cell growth characteristics, thereby allowing fine-tuning of culture medium composition to enhance cell proliferation and viability.

[0039] In some aspects, this disclosure provides methods for estimating the number of cells in a three-dimensional pluripotent stem cell culture. The methods typically include detecting the concentration of IGFBP2 in the culture supernatant. The IGFBP2 concentration is correlated with the yield and / or volume of spheroidized cell cultures. Therefore, in some embodiments, the methods of this disclosure include detecting the IGFBP2 concentration in the three-dimensional pluripotent cell culture and correlating the concentration with the formation and / or volume of spheroidized cell cultures. These methods provide a non-destructive approach to estimating the number of cells in 3D cultures and can be used to assess the formation and / or volume of spheroidized cell cultures, overcoming the challenges of conventional counting methods in complex culture systems. In some embodiments, the IGFBP2 concentration is compared to a target range (e.g., 150 ng / ml to 300 ng / ml) to estimate the number of cells in the 3D PSC culture.

[0040] In some aspects, this disclosure provides methods for evaluating confluence of pluripotent stem cell cultures. These methods typically include detecting the concentration of IGFBP2 in the culture supernatant. IGFBP2 concentration is associated with the confluence of pluripotent stem cells. Therefore, in some embodiments, the methods of this disclosure include detecting the concentration of IGFBP2 in the pluripotent stem cell culture and correlating that concentration with cell confluence. These methods can be used to assess cell confluence, providing a non-invasive tool for determining optimal cell growth conditions and passage timing. In some embodiments, IGFBP2 concentration is assessed within a target range (e.g., 150 ng / ml to 250 ng / ml) to evaluate cell confluence.

[0041] In some aspects, this disclosure provides methods for estimating cell numbers in visually challenging conditions, such as cell factories. These methods typically involve detecting the concentration of IGFBP2 in the culture supernatant. IGFBP2 concentration is correlated with cell number. Therefore, in some embodiments, the methods of this disclosure include detecting the IGFBP2 concentration in the cell factory and correlating the concentration with cell counting under visually challenging conditions. These methods can be used to estimate cell numbers in cell factories, providing a technical solution for accurate cell counting in large-scale and visually challenging environments, thus improving production efficiency. In some embodiments, the IGFBP2 concentration is compared to a target range (e.g., 150 ng / ml to 300 ng / ml for PSC cultures) to estimate the cell number in the cell factory.

[0042] In some aspects, this disclosure provides methods for monitoring cell differentiation in pluripotent stem cell cultures. These methods typically include detecting the concentration of IGFBP2 in the culture supernatant. IGFBP2 concentration is associated with cell differentiation. Therefore, in some embodiments, the methods of this disclosure include detecting the concentration of IGFBP2 in the differentiation culture and correlating said concentration with the progress of differentiation. These methods can be used to monitor cell differentiation, provide insights into the differentiation process, and optimize differentiation protocols.

[0043] In some aspects, this disclosure provides methods for evaluating the differentiation of pluripotent stem cells into specific cell lines. These methods typically include detecting IGFBP2 concentration during the differentiation process. IGFBP2 concentration is correlated with the yield of differentiated cells. Therefore, in some embodiments, the methods of this disclosure include detecting the IGFBP2 concentration in the differentiation culture and correlating that concentration with the yield of differentiated cells. These methods can be used to assess differentiation into specific cell lines, providing a quantitative approach to assess and optimize the yield of differentiated cells.

[0044] In some aspects, this disclosure provides a method for evaluating the differentiation of pluripotent stem cells into dopaminergic neurons. The method typically includes detecting the concentration of IGFBP2 in the culture supernatant at various stages of differentiation. IGFBP2 concentration is correlated with the yield of dopaminergic neurons. Therefore, in some embodiments, the method of this disclosure includes detecting the concentration of IGFBP2 in a pluripotent stem cell culture differentiating into dopaminergic neurons and correlating this concentration with the efficiency of neuronal formation. This method can be used to assess the differentiation of stem cells into dopaminergic neurons, providing a tool for optimizing the generation of dopaminergic neurons and improving their therapeutic applications. In some embodiments, the IGFBP2 concentration is evaluated against a target range (e.g., less than 500 ng / ml) to assess differentiation into dopaminergic neurons.

[0045] In some aspects, this disclosure provides methods for monitoring cell maturity in differentiated cell cultures, such as cultures of cells differentiated from PSCs like cardiomyocytes. These methods typically include detecting the concentration of IGFBP2 in the culture supernatant. IGFBP2 concentration is correlated with cell maturity. Therefore, in some embodiments, the methods of this disclosure include detecting the concentration of IGFBP2 in differentiated cell cultures undergoing maturation and correlating this concentration with the maturation process. These methods can be used to monitor cell maturity, provide insights into the maturation process, and enable optimization of maturation protocols. In some embodiments, the IGFBP2 concentration is compared to a target range (e.g., 0 ng / ml to 20 ng / ml for cultures containing cardiomyocytes) to monitor cell maturity.

[0046] In some aspects, this disclosure provides methods for assessing the maturity of differentiated cell cultures (e.g., cultures of cells differentiated from PSCs such as cardiomyocytes). These methods typically include detecting IGFBP2 concentrations during the maturation process. IGFBP2 concentrations are correlated with cell maturity. Therefore, in some embodiments, the methods of this disclosure include detecting IGFBP2 concentrations in cell cultures undergoing maturation and correlating that concentration with successful maturation and / or the yield of mature cells. These methods can be used to evaluate maturity, providing a quantitative approach to assess and optimize the yield of mature cells.

[0047] In some aspects, this disclosure provides methods for assessing the maturity of cardiomyocytes (e.g., cultures of cardiomyocytes differentiated from PSCs). These methods typically involve detecting IGFBP2 concentrations in the culture supernatant at various stages of cardiomyocyte maturation. IGFBP2 concentrations are correlated with the degree of cardiomyocyte maturation. Therefore, in some embodiments, the methods of this disclosure include detecting IGFBP2 concentrations in cultures of cardiomyocytes undergoing maturation and correlating these concentrations with the success of cardiomyocyte maturation and / or the yield of mature cardiomyocytes. These methods can be used to assess cardiomyocyte maturation, providing tools for optimizing cardiomyocyte maturation and improving therapeutic applications. In some embodiments, IGFBP2 concentrations are evaluated against a target range (e.g., 0 ng / ml to 20 ng / ml) to assess cardiomyocyte maturation.

[0048] The following sections and specific implementation schemes 1 to 142 illustrate other applications and details of using IGFBP2 concentration to assess the state and / or number of cells in culture.

[0049] 6.1 Definition Unless otherwise defined herein, scientific and technical terms used in connection with this disclosure shall have the meanings commonly understood by one of ordinary skill in the art. Exemplary methods and materials are described below, but similar or equivalent methods and materials may also be used in the practice or testing of this disclosure. In case of conflict, this specification (including definitions) shall prevail. Generally, nomenclature and techniques related to cell and tissue culture, molecular biology, immunology, microbiology, genetics, analytical chemistry, synthetic organic chemistry, pharmaceutical and medicinal chemistry, and protein and nucleic acid chemistry and hybridization described herein are well known and commonly used in the art. Enzymatic reactions and purification techniques are performed according to the manufacturer's instructions as commonly practiced in the art or as described herein. Furthermore, unless the context requires otherwise, singular terms shall include plural terms, and plural terms shall include singular terms. Throughout this specification and embodiments, the words “have” and “comprise,” or variations such as “has,” “having,” “comprises,” or “comprising,” shall be understood to imply inclusion of the said integers or groups of integers, but not to exclude any other integers or groups of integers. All publications and other references mentioned in this article are incorporated herein by reference in their entirety. Although this article cites numerous references, such citations do not constitute an acknowledgment that any of these references constitutes part of common general knowledge in the field.

[0050] Receptor antibody: As used herein, the term "receptor antibody" refers to a conjugated antibody or fragment thereof used in HTRF or similar immunological assays. The receptor antibody is conjugated to a fluorophore or another label having relatively short fluorescence. When approached by a donor antibody, the fluorophore of the receptor antibody transfers energy from the fluorophore of the donor antibody, at which point the fluorophore of the receptor antibody emits a detectable signal.

[0051] Antibody: As used herein, the term "antibody" refers to a naturally occurring or engineered immunoglobulin molecule or its immunologically active fragment, i.e., the antigen-binding portion. The term "antibody" includes both monoclonal and polyclonal antibodies.

[0052] Capture antibody: As used herein, the term "capture antibody" refers to an antibody or fragment thereof immobilized on a solid surface, such as the surface of a well, for example, the surface of a cell culture plate used for ELISA or similar immunological assays. The capture antibody recognizes a specific biomolecule (e.g., IGFBP2) and binds to and retains that biomolecule.

[0053] Cell counting: As used herein, the terms “cell count” and “cell counting” refer to the quantification or counting of cultured cells. In various embodiments, the cultured cells are adhered to a surface (e.g., the surface of a cell culture vessel, dish, or well) or suspended in a culture medium.

[0054] Cell factory: As used herein, the term “cell factory” refers to a large-scale cell culture system that provides a large growth surface in a small area, such as two or more cell culture chambers stacked together as a single unit, which have shared vents and filling ports to simplify the maintenance and handling of the cultured cells.

[0055] Detection antibody: As used herein, the term "detection antibody" refers to an antibody in which a detection component is integrated, such as for ELISA or similar immunological assays. The detection antibody may be conjugated to an enzyme, which produces a detectable product upon the addition of a substrate, or conjugated to a fluorescent or radiolabeled marker, which can be detected without the addition of a substrate.

[0056] Donor antibody: As used herein, the term "donor antibody" refers to a conjugated antibody or fragment thereof used in HTRF or similar immunological assays. The donor antibody is conjugated to a fluorophore having a relatively long fluorescence duration. When approached by a receptor antibody, the fluorophore of the donor antibody transfers energy to the fluorophore of the receptor antibody, at which point the fluorophore of the receptor antibody emits a detectable signal.

[0057] Enzyme-linked immunosorbent assay (ELISA): As used herein, the term “enzyme-linked immunosorbent assay” or “ELISA” refers to an immunological method for quantifying a specific protein, peptide, or polypeptide in a complex mixture, such as cell culture medium, serum, cell extracts, tissue extracts, saliva, and other bodily fluids. In the context of the methods disclosed herein, ELISA is used to quantify the concentration of IGFBP2 in unreplenished culture medium samples.

[0058] Encoding: The term “encoding” in relation to nucleic acids (DNA or RNA) refers to the nucleotide sequence of a nucleic acid that contains amino acids that encode polypeptides or nucleotides that encode RNA.

[0059] Fluorescence resonance energy transfer (FRET): As used herein, the terms "fluorescence resonance energy transfer," "Förster resonance energy transfer," or "FRET" refer to a distance-dependent physical process through which energy is transferred nonradiatively from an excited donor fluorophore to an acceptor fluorophore via long-range intermolecular dipole-dipole coupling. Due to its sensitivity to the distance between the donor and acceptor fluorophores, FRET has been used to study molecular colocalization and / or interactions.

[0060] Homogeneous time-resolved fluorescence (HTRF): As used herein, the terms “homogeneous time-resolved fluorescence,” “HTRF,” “time-resolved fluorescence resonance energy transfer,” or “TR-FRET” refer to an immunological method that combines fluorescence resonance energy transfer (FRET) technology with time-resolved fluorescence detection. HTRF is used to quantify specific proteins, peptides, or polypeptides in a homogeneous form, thereby allowing for high-throughput screening. In the context of the methods disclosed herein, HTRF can be used to quantify the concentration of IGFBP2 in unfed culture medium samples.

[0061] Engineered Cells: As used herein, the terms “engineered cell” and “recombinant cell” refer to cells that have been genetically engineered, for example, by introducing heterologous polypeptides or nucleic acids to express a specific protein or peptide, such as IL12. It should be understood that such terms are intended to refer not only to specific subject cells but also to the progeny of such cells. Engineered or recombinant cells can be obtained by altering the cell's genome (e.g., through gene editing) and / or by introducing heterologous nucleic acids into the cell (e.g., via viral or non-viral delivery (e.g., via electroporation, nuclear transfection, lipid transfection, or microinjection) replicating or non-replicating nucleic acids). Cells can be engineered to express one or more genes, RNA, proteins, peptides, or any combination of one or more of the foregoing in ectopic locations.

[0062] Final concentration: As used herein, the term “final concentration” refers to the concentration detected in the final detection step of an IGFBP2 assay.

[0063] Final measurement (step): As used herein, the terms “final measurement” and “final measurement step” refer to the final concentration determination of IGFBP2 before manipulating the culture (e.g., differentiation, harvesting, preservation, subculturing, destruction, etc.).

[0064] Initial concentration: As used herein, the term “first concentration” refers to the concentration detected in the initial detection step of an IGFBP2 assay.

[0065] Initial measurement (step): As used herein, the terms “initial concentration” and “first measurement step” refer to the initial concentration measurement of IGFBP2 (e.g., after cells are seeded or passaged in the culture).

[0066] IGFBP2 assay: As used herein, the term “IGFBP2 assay” refers to an assay involving the detection of IGFBP2 levels (e.g., IGFBP2 concentration) in cell culture medium, such as two, three, four or more assays performed over multiple days.

[0067] iPSC: As used herein, the terms “induced pluripotent stem cell” and “iPSC” refer to a class of pluripotent stem cells artificially prepared from non-pluripotent cells (e.g., adult somatic cells, partially differentiated cells, or terminally differentiated cells (e.g., fibroblasts, hematopoietic lineage cells, myocytes, neurons, epidermal cells, etc.)) by introducing cells or exposing cells to one or more reprogramming factors. iPSCs can be derived from a variety of different cell types, including terminally differentiated cells. iPSCs have an embryonic stem cell (ES)-like morphology, growing as flat colonies with a high nucleus-to-cytoplasmic ratio, well-defined borders, and prominent nuclei. In addition, iPSCs express one or more key pluripotency markers known to those skilled in the art, including but not limited to alkaline phosphatase, SSEA3, SSEA4, SOX2, OCT3 / 4, NANOG, TRA160, TRA181, TDGF1, Dnmt3b, Fox03, GDF3, Cyp26al, TERT, and zfp42.

[0068] Examples of methods for generating and characterizing iPSCs can be found, for example, in US Patent Publications US20090047263, US20090068742, US20090191159, US20090227032, US20090246875, and US20090304646, and PCT Patent Publications WO2013177133 and WO2022204567, the disclosures of which are incorporated herein by reference. Typically, to generate iPSCs, somatic cells need to be reprogrammed with reprogramming factors known in the art (e.g., OCT4, SOX2, KLF4, MYC, NANOG, Lin28, GLIS1, BCL-XL, etc.) to transform them into pluripotent stem cells. In some implementations, iPSCs are generated by introducing nucleic acids encoding multiple mountain factors (e.g., two, three, or all four of OCT4, KLF4, SOX2, and c-MYC) and optionally one or more additional reprogramming factors (e.g., BCL-XL) into somatic cells and culturing the cells under conditions expressing multiple mountain factors and optionally one or more reprogramming factors.

[0069] Maturation: As used herein, “maturation” refers to the cell development process in which cells reach their fully developed state. In some embodiments, cell cultures containing cells that have undergone maturation (e.g., cardiomyocytes) will show a decrease in cell proliferation as maturation progresses.

[0070] Normalization marker: As used herein, a “normalization marker” is a molecule expressed in multiple cell types, such as proteins, peptides, or another biomolecule expressed in multiple cell types, including pluripotent cells, such as iPSCs and their derivatives, and can be used as a substitute for housekeeping molecules that normalize detection in living cells (e.g., due to their consistent and / or predictable expression levels). IGFBP2 can be used as a normalization marker for cultured cells, as described herein, for the normalization of other assays in different batches of experiments.

[0071] Nucleic acid: As used herein, the terms “nucleic acid,” “oligonucleotide,” and “nucleic acid” refer to at least two nucleotides covalently linked together. Nucleic acids can be single-stranded or double-stranded, or may contain portions of both double-stranded and single-stranded sequences. Nucleic acids can be DNA (both genomic and cDNA), RNA, or hybrids, wherein the nucleic acid may contain combinations of deoxyribonucleotides and ribonucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, and isoguanine. Nucleic acids can be obtained by chemical synthesis or by recombinant methods. The description of single-stranded also defines the sequence of the complementary strand. Therefore, references to single-stranded nucleic acids herein also cover the complementary strand of the single-stranded nucleic acid described.

[0072] Polypeptides, peptides, and proteins: As used herein, the terms “polypeptide,” “peptide,” and “protein” refer to polymers of any length that contain or are composed of amino acids.

[0073] Pluripotency: As used herein, the term “pluripotent” or “pluripotency” refers to the ability of a cell to self-renew and differentiate into cells from any of the three germ layers: endoderm, mesoderm, or ectoderm. “Pluripotent stem cells” or “PSCs” include, for example, embryonic stem cells derived from the inner cell mass of the blastocyst or through somatic cell nuclear transfer, as well as iPSCs derived from non-pluripotent cells.

[0074] Seeding density: As used herein, the term “seeding density” or “cell seeding density” refers to the number of cells introduced per unit area into a container suitable for cell growth, such as, but not limited to, wells (e.g., in multiwell plates), flasks, culture dishes, or roller flasks. Typically, the container is sterile at the time of seeding. The container may be empty or contain a substrate suitable for cell growth.

[0075] Secreted molecules: As used herein, the term “secreted molecule” refers to a biomolecule that is produced in and released from a cell. Exemplary types of secreted molecules include, but are not limited to, secreted proteins and peptides, such as growth factors, interleukins, chemokines, interferons, lymphokines, hormones, and neurotransmitters.

[0076] Single-cell suspension: As used herein, the term "single-cell suspension" or its equivalents refer to a mixture of fluid and cells, or more generally, multiple cells, that are separated from each other (e.g., do not aggregate), and that can be prepared by any available mechanical, biological, or chemical means. Single-cell suspensions described herein are typically formulations of live iPSCs or iPSC-derived cells suspended in physiological solutions, such as basal salt solutions, saline solutions, or cell culture media. Several methods exist for dissociating cell clusters from primary tissues, cultured adherent cells, and cell aggregates to form single-cell suspensions, including, but not limited to, methods of cell dissociation by physical forces (e.g., mechanical dissociation, such as cell scraping, grinding through narrow-pore pipettes, fine-needle aspiration, vortex depolymerization, and forced filtration through fine nylon or stainless steel mesh), enzymatic dissociation methods (e.g., trypsin, collagenase, Accutase™-mediated dissociation), or combinations thereof. Furthermore, methods and culture conditions that support the growth and viability of single-cell suspensions of iPSCs can be used for amplification, cell sorting and limited seeding in multi-well plate assays, and to automate culture procedures, cell counting and clonal amplification.

[0077] Spheroids: As used herein, the term "spheroid" refers to a self-assembled aggregate or cluster of cells capable of forming without a scaffold. Typically, spheroids are spherical and form under conditions where cell-cell interactions are more dominant than cell-substrate interactions. Spheroids can be highly organized, with well-defined morphologies mimicking diverse in vivo cell interactions, or they can be simple clusters of cells aggregated or adhered together, possessing minimal organization associated with their tissue of origin.

[0078] Subsequent concentration: As used herein, the term “subsequent concentration” refers to any concentration detected between the initial and final detection steps in an IGFBP2 assay.

[0079] Subsequent measurement (step): As used herein, the terms “subsequent measurement” and “subsequent measurement step” refer to any and all concentration measurements between the initial and final measurement steps in an IGFBP2 assay.

[0080] Unfed culture: As used herein, the terms "unfed culture," "unfed cell culture," etc., refer to cell cultures in which the culture medium has not been removed, altered, or replenished for at least 12 hours (e.g., at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 24 hours, at least 36 hours, or at least 48 hours). In some embodiments, an unfed culture is a culture in which the culture medium has not been removed, altered, or replenished for at least 15 hours, at least 18 hours, or at least 20 hours.

[0081] Unfed medium: As used herein, the terms “unfed medium,” “unfed media,” “spent medium,” or “spent media” refer to a cell culture medium or medium containing cells in a culture vessel, wherein the medium or medium has not been removed, altered, or replenished for at least 12 hours (e.g., at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 24 hours, at least 36 hours, or at least 48 hours). In some embodiments, the unfed medium has not been removed, altered, or replenished for at least 15 hours, at least 18 hours, or at least 20 hours.

[0082] Western blotting: As used herein, the terms “western blotting” or “immunoblotting” refer to an analytical technique for detecting specific proteins, peptides, or polypeptides in complex mixtures (e.g., cell culture media, serum, cell extracts, tissue extracts, saliva, and other bodily fluids), wherein the proteins, peptides, or polypeptides in the mixture are separated by gel electrophoresis, transferred to a suitable surface (e.g., a membrane), and detected by immunoassay. In the methods of this disclosure, western blotting can be used to detect the concentration of IGFBP2 in a culture medium sample.

[0083] 6.2 IGFBP2 This disclosure provides IGFBP2 assays for a variety of applications, such as as a cell count measurement or as a standardized biomarker.

[0084] IGFBP2 is a secreted protein produced and released from a variety of cells, including but not limited to pluripotent cells such as iPSCs and their derivatives. In the human body, IGFBP2 can be secreted into the bloodstream, where it binds to insulin-like growth factors IGF-I and IGF-II with high affinity, or it can remain intracellularly, interacting with many different ligands. The binding of IGFBP2 to IGF can prolong the half-life of these growth factors and regulate the interaction of IGF with its cell surface receptors.

[0085] The IGFBP2 assay of this disclosure can detect the concentration of wild-type or variant IGFBP2 amino acid sequences. Typically, the IGFBP2 is mammalian IGFBP2.

[0086] In some embodiments, the mammalian IGFBP2 is human IGFBP2. The full-length human IGFBP2 is 325 amino acids long, corresponds to Uniprot identification number P18065, and has the following amino acid sequence, wherein the signal peptide sequence is underlined: MLPRVGCPALPLPPPPLLPLLLLLLGASGGGGGARAEVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKP LKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ (SEQ ID NO:1) Mature human IGFBP2, which does not contain the signal peptide, has the following amino acid sequence: AEVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKP LKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ (SEQ ID NO:2) In some embodiments, the human IGFBP2 is a splice variant of IGFBP2. The 181-amino acid splice variant of IGFPB2 corresponding to Uniprototype C9JMY1 has the following amino acid sequence: MPCNNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ (SEQ ID NO:3) In some embodiments, the human IGFBP2 splice variant is 98 amino acids long, corresponding to the Uniprot identification number H7CH0, and has the following amino acid sequence: KHHLGLEEPKKLRPPPARQLLAELASGACFVGLLSSLRASPAVCACRLPANRNWTRSWSGSPPCAFRMSGALWSTSTPCTSPTVTSMACTTSNSARCL (SEQ ID NO:4) In some embodiments, the human IGFBP2 splice variant is 78 amino acids long, corresponding to Uniprot identification number C9JW52, and has the following amino acid sequence: MNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLP (SEQ ID NO:5) In some embodiments, the mammalian IGFBP2 is mouse (e.g., mouse) IGFBP2. Mouse IGFBP2 has the Uniprot recognition number P47877 and the following amino acid sequence, wherein the signal sequence is underlined: MLPRLGGPALPLLLPSLLLLLLLGAGGCGPGVRA EVLFRCPPCTPERLAACGPPPDAPCAELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTCEKRRVGTTPQQVADSDDDHSEGGLVENHVDGTMNMLGGGSSAGRKPLKSGMKEL AVFREKVNEQHRQMGKGAKHLSLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDDRGPLEHLYSLHIPNCDKHGRYNLKQCKMSLNGQRGECWCVNPNTGKPIQGAPTIRGDPECHLFYNEQQETGGAHAQSVQ (SEQ ID NO:6) Mature mouse IGFBP2 lacking the signal peptide has the following amino acid sequence: EVLFRCPPCTPERLAACGPPPDAPCAELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTCEKRRVGTTPQQVADSDDDHSEGGLVENHVDGTMNMLGGGSSAGRKPLKSGMKEL AVFREKVNEQHRQMGKGAKHLSLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDDRGPLEHLYSLHIPNCDKHGRYNLKQCKMSLNGQRGECWCVNPNTGKPIQGAPTIRGDPECHLFYNEQQETGGAHAQSVQ (SEQ ID NO:7) In some implementations, the mammalian IGFBP2 is a monkey (e.g., the black-faced green monkey). C. sabaeus Monkey IGFBP2. Monkey IGFBP2 has the Uniprototype identifier A0A0D9R9L4 and the following amino acid sequence, wherein the signal sequence is underlined: MLPRVGCPALPLPPPPLLPLLLLLLGASGGGGGAHA EVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKP LKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ (SEQ ID NO:8) Mature monkey IGFBP2 lacking the signal peptide has the following amino acid sequence: EVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKP LKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ (SEQ IDNO:9) In some embodiments, the mammalian IGFBP2 is hamster (e.g., Chinese hamster) IGFBP2. Hamster IGFBP2 has the Uniprot identification number A0A8C2MM64 and the following amino acid sequence, wherein the signal sequence is underlined: MLPRLGGPALSLLLPSLLLLLLLGAGGCGPGVRA EVLFRCPPCTPERLAACGPPPDGPCAELVREPGCGCCSVCARLEGEACGVYTPRCAQTLRCYPNPGSELPLKALVSGAGTCEKSRVGATPQQVADNGDDHSEGGLVENHVDGTMNMLGGGSSAGRKPLKSGMKELA VFREKVSEQHRQMGKGGKHHLSLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDDRGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQETGGAHAQRVQ (SEQ ID NO:10) Mature hamster IGFBP2 lacking the signal peptide has the following amino acid sequence: EVLFRCPPCTPERLAACGPPPDGPCAELVREPGCGCCSVCARLEGEACGVYTPRCAQTLRCYPNPGSELPLKALVSGAGTCEKSRVGATPQQVADNGDDHSEGGLVENHVDGTMNMLGGGSSAGRKPLKSGMKELA VFREKVSEQHRQMGKGGKHHLSLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDDRGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQETGGAHAQRVQ (SEQ ID NO:11) 6.3. IGFBP2 Measurement This disclosure provides an IGFBP2 assay, typically performed when the IGFBP2 concentration reflects the cell count or cell health in the culture. This IGFBP2 assay may require repeated measurements of IGFBP2 concentration throughout the lifespan of the cell culture. Typically, IGFBP2 concentration is detected by removing an appropriate volume of cell culture medium from a cell culture vessel containing live cells and using a suitable assay method to determine the IGFBP2 concentration in the cell culture medium. Suitable assay methods are further described in Section 6.3.1.

[0087] In some implementations, IGFBP2 measurement includes: (a) Initial detection steps, including detecting the initial concentration of IGFBP2 in the culture medium of the cell culture; (b) Optionally, subsequent detection steps include detecting at least one subsequent concentration of IGFBP2 in the culture medium of the cell culture; and (c) Optionally, the final detection step includes detecting the final concentration of IGFBP2 in the culture medium of the cell culture.

[0088] Typically, the cell culture medium used to detect IGFBP2 concentration is unfed medium. The detection time relative to the time when the cell culture is fed is further described in Section 6.3.2.

[0089] In some implementations, the initial detection step is followed by one or more subsequent detection steps and / or a final detection step. The frequency and timing of the subsequent and / or final detection steps are further described in Section 6.3.2.

[0090] 6.3.1. Measurement Method The concentration of IGFBP2 in cell culture medium can be detected by taking an appropriate volume of cell culture medium from a culture vessel containing cells (e.g., a culture dish) and measuring the concentration of IGFBP2 in the sampled cell culture medium using a suitable assay method (e.g., an immunological assay). Cell culture medium may contain live cells, dead cells, or both live and dead cells.

[0091] Anti-IGFBP2 antibodies, which can be used in immunoassays to determine the concentration of IGFBP2 in cell culture medium, can be commercially available or readily produced by practitioners using common procedures known in the art.

[0092] Non-limiting examples of anti-IGFBP2 antibodies that can be used for immunological assays to identify and bind IGFBP2 in this disclosure are listed in Table 1 below. Non-limiting examples of immunological assays that can be used to determine the concentration of IGFBP2 in cell culture media include enzyme-linked immunosorbent assay (ELISA) and homogeneous time-resolved fluorescence (HTRF), which are further described in Sections 6.3.1.1 and 6.3.1.2, respectively.

[0093] In some embodiments, the same method is used to detect all IGFBP2 concentrations in the same culture medium. In other embodiments, two or more methods are used to detect different IGFBP2 concentrations in the same culture medium.

[0094] In some embodiments, the initial detection step utilizes ELISA. In other embodiments, the initial detection step utilizes HTRF. In still other embodiments, the initial detection step utilizes Western blotting.

[0095] In some embodiments, one or more (or all) of the subsequent detection steps utilize ELISA. In other embodiments, one or more (or all) of the subsequent detection steps utilize HTRF. In some embodiments, one or more (or all) of the subsequent detection steps utilize Western blotting.

[0096] In some implementations, the final detection step utilizes ELISA. In other implementations, the final detection step utilizes HTRF. In still other implementations, the final detection step utilizes Western blotting.

[0097] In some implementations, the initial detection step, all subsequent detection steps, and the final detection step in the IGFBP2 assay all utilize ELISA.

[0098] In some implementations, the initial detection step, all subsequent detection steps, and the final detection step in the IGFBP2 assay all utilize HTRF.

[0099] In some implementations, Western blotting is used in the initial detection step, all subsequent detection steps, and the final detection step in the IGFBP2 assay.

[0100] 6.3.1.1. ELISA ELISA is an immunological assay commonly used to detect antibodies, antigens, proteins, and glycoproteins in biological samples, and can also be used to determine the concentration of IGFBP2 in cell culture media samples.

[0101] ELISA-based detection of IGFBP2 concentration in cell culture medium involves four steps. In the first step, protein standards and cell culture medium samples are added to appropriate wells of a plate coated with capture antibodies (e.g., a 96-well plate), and the plate is then incubated at room temperature for a suitable incubation duration to allow IGFBP2 in the culture medium sample to bind to the capture antibodies (initial incubation step). In the second step, the wells are washed, an appropriate conjugation antibody is added to each well, and the plate is incubated at room temperature for a suitable incubation duration to allow the conjugation antibody to bind to IGFBP2 immobilized by the capture antibody (second incubation step). In the third step, unbound conjugation antibodies are washed away, a substrate solution is added to the wells, and the plate is incubated in the dark to allow color development for a suitable incubation duration (third incubation step). In the final step, color development is stopped by adding a stop solution, and the color intensity in each well is detected at an appropriate wavelength (e.g., 450 nm) (detection step), where the color intensity in a well is proportional to the amount of IGFBP2 in that well. An ELISA calibration curve is created using standards of known concentrations, and the concentration of IGFBP2 in the culture medium sample can be determined by comparing the signal observed therein with the signal observed in the calibration.

[0102] In some implementations, automated systems are used to perform ELISA. Automated ELISA systems that can be used with the disclosed IGFBP2 assay include, for example, microfluidic-based immunoassay systems, such as ELLA. TM Automated Immunoassay Systems (R&D Systems) and Agility ® The ELISA system (Dynex Technologies), and the systems described in patent publications EP3311163B1 and WO2013010178A1 (each of which is incorporated herein by reference in its entirety).

[0103] In some implementations, the incubation period in the first incubation step is 1 to 2 hours.

[0104] In some implementations, the incubation period in the first incubation step is 2 hours.

[0105] In some implementations, the incubation period in the second incubation step is 1 to 2 hours.

[0106] In some implementations, the incubation period in the second incubation step is 1 hour.

[0107] In some implementations, the incubation period in the third incubation step is from 15 minutes to 1 hour.

[0108] In some implementations, the incubation period in the third incubation step is half an hour.

[0109] In some implementations, ELISA is performed to determine the initial concentration of IGFBP2 in the culture medium of the cell culture.

[0110] In some embodiments, ELISA is performed to determine one or more subsequent concentrations of IGFBP2 in the cell culture medium. In some embodiments, ELISA is performed to determine only one subsequent concentration of IGFBP2 in the cell culture medium. In other embodiments, ELISA is performed to determine multiple subsequent concentrations of IGFBP2 in the cell culture medium.

[0111] In some implementations, ELISA is performed to determine the final concentration of IGFBP2 in the culture medium of the cell culture.

[0112] In some implementations, ELISA is performed to determine the initial concentration of IGFBP2, one or more subsequent concentrations of IGFBP2, and the final concentration of IGFBP2.

[0113] 6.3.1.2. Homogeneous Time-Resolved Fluorescence (HTRF) Homogeneous time-resolved fluorescence (HTRF) is an immunological assay that combines time-resolved fluorescence (TRF) detection with fluorescence resonance energy transfer (FRET), eliminating transient background fluorescence. HTRF-based cell assays are described in U.S. Patent No. 5,527,684, the disclosure of which is incorporated herein by reference.

[0114] The detection of IGFBP2 concentration in cell culture media based on HTRF involves adding a standard or cell culture medium sample to a reservoir, such as the wells of a suitable 96-well plate, and incubating the standard and sample together with two anti-IGFBP2 antibodies provided at a suitable weight ratio (e.g., 1:1, 1:2, 2:5, 1:4, 1:5, 1:8, 1:10, 1:16, 1:20, 1:40, 5:4, 5:2, 2:1, 4:1, or 5:1) for an appropriate duration (a double antibody incubation step), wherein the first antibody is conjugated to a donor (donor antibody) and the second antibody is conjugated to a receptor (receptor antibody). In some embodiments, the two anti-IGFBP2 antibodies are in a weight ratio ranging from 1:2 to 2:1, optionally at 1:1. After the double antibody incubation step is completed, light emission from each well is detected on an HTRF-compatible reader (e.g., a microplate reader), wherein the emission of the receptor antibody is proportional to the level of interaction. An HTRF calibration curve was created using IGFBP2 standards of known concentration, and the concentration of IGFBP2 in the culture medium sample could be determined by comparing the signal observed therein with the signal observed in the calibration.

[0115] In some implementations, the concentrations of donor and recipient antibodies are provided at a weight ratio of 1:20.

[0116] In some other implementations, the donor antibody and the recipient antibody are provided at a weight ratio of 1:40.

[0117] In some implementations, the incubation duration of the dual antibody incubation step is 2 to 6 hours (e.g., 2-6 hours, 2-5 hours, 2-4 hours, 2-3 hours, 3-4 hours, 3-5 hours, 3-6 hours, 4-5 hours, 4-6 hours, or 5-6 hours).

[0118] In various implementations, the incubation duration of the dual antibody incubation step is 3 to 5 hours.

[0119] In some implementations, the incubation period for the dual antibody incubation step is 3 hours.

[0120] In some implementations, the incubation period for the dual antibody incubation step is 4 hours.

[0121] In some implementations, the incubation period for the dual antibody incubation step is 5 hours.

[0122] In some implementations, HTRF is performed to determine the initial concentration of IGFBP2 in the culture medium of the cell culture.

[0123] In some embodiments, HTRF is performed to determine one or more subsequent concentrations of IGFBP2 in the cell culture medium. In some embodiments, HTRF is performed to determine only one subsequent concentration of IGFBP2 in the cell culture medium. In other embodiments, HTRF is performed to determine multiple subsequent concentrations of IGFBP2 in the cell culture medium.

[0124] In some implementations, HTRF is performed to determine the final concentration of IGFBP2 in the culture medium of the cell culture.

[0125] In some implementations, HTRF is performed to determine the initial concentration of IGFBP2, one or more subsequent concentrations of IGFBP2, and the final concentration of IGFBP2.

[0126] 6.3.1.3. Western Blotting Western blotting, or immunoblotting, is an analytical technique used to detect specific proteins in a given sample, such as cell lysates, cell or tissue homogenates, or other protein-containing samples, wherein the proteins in the sample are separated by gel electrophoresis under non-denaturing (native) or denaturing conditions, transferred from a gel (e.g., a polyacrylamide gel) to a suitable surface (e.g., a nitrocellulose membrane or PVDF membrane), detected by an antibody detection method, and quantified using suitable image analysis software (e.g., ImageJ software). Western blotting methods are described in U.S. Patent No. 8,592,141 and PCT Publication No. 2012 / 057689 A1, the disclosures of which are incorporated herein by reference.

[0127] In some implementations, proteins in cell lysates are separated under denaturing conditions.

[0128] In other embodiments, proteins in cell lysates are isolated under non-denaturing conditions.

[0129] In some implementations, the protein is transferred from the gel onto a nitrocellulose membrane.

[0130] In some implementations, proteins are transferred from the gel onto a PVDF membrane.

[0131] In some embodiments, the protein-containing membrane is incubated with an unlabeled antibody against IGFBP2 (primary antibody) and then with a labeled antibody against the primary antibody (secondary antibody).

[0132] In some implementations, the second antibody has a fluorescent label or tag.

[0133] In some implementations, the second antibody has a chemiluminescent label or tag.

[0134] In some implementations, the second antibody has a radiolabel or tag.

[0135] In some implementations, Western blotting is used to quantify the concentration of IGFBP2 in a sample only.

[0136] In some implementations, Western blotting is performed to determine the initial concentration of IGFBP2 in the culture medium of the cell culture.

[0137] In some embodiments, Western blotting is performed to determine one or more subsequent concentrations of IGFBP2 in the cell culture medium. In some embodiments, Western blotting is performed to determine only one subsequent concentration of IGFBP2 in the cell culture medium. In other embodiments, Western blotting is performed to determine multiple subsequent concentrations of IGFBP2 in the cell culture medium.

[0138] In some implementations, Western blotting is performed to determine the final concentration of IGFBP2 in the culture medium of the cell culture.

[0139] In some implementations, Western blotting is performed to determine the initial concentration of IGFBP2, one or more subsequent concentrations of IGFBP2, and the final concentration of IGFBP2.

[0140] 6.3.2. Measurement Time In some implementations, IGFBP2 detection is performed on unreplenished culture medium samples taken at least 12 hours after previous replenishment (e.g., at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, or at least 24 hours).

[0141] In some implementations, IGFBP2 detection is performed on unfed culture medium samples taken 12 hours after previous feeding and optionally at least 30 or 36 hours after previous feeding.

[0142] In some implementations, IGFBP2 detection is performed on unfed culture medium samples taken 16 hours after previous feeding and optionally at least 30 or 36 hours after previous feeding.

[0143] In some implementations, IGFBP2 detection is performed on unfed culture medium samples taken 18 hours after previous feeding and optionally at least 30 or 36 hours after previous feeding.

[0144] In some implementations, IGFBP2 detection is performed on unfed culture medium samples taken 20 hours after previous feeding and optionally at least 30 or 36 hours after previous feeding.

[0145] In some implementations, IGFBP2 detection is performed on unfed culture medium samples taken 22 hours after previous feeding and optionally at least 30 or 36 hours after previous feeding.

[0146] In some implementations, IGFBP2 detection is performed on unfed culture medium samples taken 24 hours after previous feeding and optionally at least 30 or 36 hours after previous feeding.

[0147] In various implementations, samples of unfed culture medium are taken 12–36 hours, 15–30 hours, 18–24 hours, or 20–24 hours after previous feeding. In some implementations, samples of unfed culture medium are taken at 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 hours, or longer after previous feeding.

[0148] In some embodiments, the initial detection is performed by measuring the IGFBP2 concentration in unfed medium sampled at least 12 hours after previous feeding. In various embodiments, the initial detection is performed by measuring the IGFBP2 concentration in unfed medium sampled 12–36 hours, 15–30 hours, 18–24 hours, or 20–24 hours after previous feeding. In some embodiments, the initial detection is performed by measuring the IGFBP2 concentration in unfed medium sampled at 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 hours, or longer after previous feeding.

[0149] In some embodiments, one or more follow-up assays are performed by detecting the IGFBP2 concentration in unfed medium sampled at least 12 hours after previous feeding. In various embodiments, one or more follow-up assays are performed by detecting the IGFBP2 concentration in unfed medium sampled 12-36 hours, 15-30 hours, 18-24 hours, or 20-24 hours after previous feeding. In some embodiments, the one or more follow-up assays are performed by detecting the IGFBP2 concentration in unfed medium sampled at 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 hours, or longer after previous feeding.

[0150] In some embodiments, IGFBP2 detection is performed by detecting the IGFBP2 concentration in unreplenished medium, wherein the first detection step, one or more subsequent detection steps (if performed), and / or the final detection step (if performed) are performed on unreplenished medium sampled at least 12 hours after previous replenishment. In various embodiments, in each case, the unreplenished medium is sampled at 12-36 hours, 15-30 hours, 18-24 hours, or 20-24 hours after previous replenishment. In some implementations, the initial detection step, one or more subsequent detection steps (if performed), and / or the final detection step (if performed) are performed on unreplenished culture media sampled 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 hours, or longer after previous replenishment.

[0151] In some implementations, the first concentration detection of IGFBP2 is followed by at least one subsequent concentration detection of IGFBP2, wherein each subsequent concentration detection is repeated using a new sample of unfed medium when the cell culture is not fed.

[0152] In some embodiments, subsequent detection steps include detecting multiple subsequent concentrations of IGFBP2 in the culture medium of the cell culture, wherein the detection of subsequent concentrations is repeated once daily, twice daily, or every other day. In some embodiments, the first of the subsequent detection steps is performed on cell culture medium sampled one day to one week (e.g., one day, two days, three days, four days, five days, six days, or seven days) after the first detection step.

[0153] In some embodiments, the subsequent detection steps include detecting multiple subsequent concentrations of IGFBP2 in the culture medium of the cell culture, wherein the detection of subsequent concentrations is repeated daily for at least 3 days, at least 4 days, or at least 5 days. In some embodiments, the first of the subsequent detection steps is performed on cell culture medium sampled one day to one week (e.g., one day, two days, three days, four days, five days, six days, or seven days) after the first detection step.

[0154] In some embodiments, the subsequent detection steps include detecting multiple subsequent concentrations of IGFBP2 in the culture medium of the cell culture, wherein the detection of subsequent concentrations is repeated twice daily for at least 3 days, at least 4 days, or at least 5 days. In some embodiments, the first of the subsequent detection steps is performed on cell culture medium sampled one day to one week (e.g., one day, two days, three days, four days, five days, six days, or seven days) after the first detection step.

[0155] In other embodiments, the subsequent detection steps include detecting multiple subsequent concentrations of IGFBP2 in the culture medium of the cell culture, wherein the detection of subsequent concentrations is repeated every other day for a period of at least 6 days, at least 8 days, at least 10 days, at least 12 days, at least two weeks, or at least three weeks. In some embodiments, the first of the subsequent detection steps is performed on cell culture medium sampled one day to one week (e.g., one day, two days, three days, four days, five days, six days, or seven days) after the first detection step.

[0156] In some embodiments, the subsequent detection steps include detecting multiple subsequent concentrations of IGFBP2 in the cell culture medium, wherein the subsequent concentrations are repeated every other day for up to four weeks. In some embodiments, the first subsequent detection step is performed on cell culture media sampled one day to one week (e.g., one day, two days, three days, four days, five days, six days, or seven days) after the initial detection step.

[0157] IGFBP2 assays are typically performed on unreplenished culture medium. After removing the unreplenished cell culture medium sample used for IGFBP2 concentration detection, the cell culture can be replenished and placed in an incubator until the next assay. In some embodiments, the cell culture is replenished daily.

[0158] 6.4. Cell Culture The method for detecting IGFBP2 concentration in cell culture medium samples disclosed herein can be used for (i) cultured cells and (ii) any suitable type of cells capable of expressing IGFBP2. The cultured cells used for detecting IGFBP2 concentration may be derived from established cell lines or may be primary cells.

[0159] In some embodiments, the cultured cells are cell lines. In some embodiments, the cell lines are mammalian cell lines. Non-limiting examples of mammalian cell lines include human embryonic kidney (HEK) cells (e.g., HEK293 cells), Chinese hamster ovary cells (CHO cells), HeLa cells, pluripotent stem cell (PSC) cell lines (e.g., iPSC) and COS-7 cells.

[0160] In some implementations, the cultured cells are primary cells, where “primary cells,” “primary cell lines,” and “primary cultures” are used interchangeably herein and refer to cells and cell cultures derived from a subject and permitted to grow in vitro for a limited number of passages (e.g., culture division). For example, primary cultures include cultures that have undergone 0, 1, 2, 4, 5, 10, or 15 passages, but have not experienced a sufficient number of crisis stages. Primary cell lines may be maintained in vitro for fewer than 10 passages.

[0161] Any type of cell can be used (e.g., stem cells (e.g., human embryonic stem cells (hESC), pluripotent stem cells (PSC), induced pluripotent stem cells (iPSC), germ cells); somatic cells (e.g., fibroblasts, hematopoietic cells, neurons, glial cells, oligodendrocytes, muscle cells, bone cells, hepatocytes, pancreatic cells), myeloid cells or myeloid progenitor cells (e.g., primitive myeloid progenitor cells), microglia or microglia progenitor cells, T cells (e.g., CD4+ T cells, such as Treg)).

[0162] In some implementations, the mammalian cultured cells are derived from human cells.

[0163] In some implementations, the host cell is a pluripotent stem cell (PSC), as described in Section 6.4.1.

[0164] If the cultured cells are primary cells, they can be harvested from an individual using any suitable method. For example, leukocytes can be harvested using suitable methods such as apheresis, leukocytapheresis, or density gradient separation, while cells from tissues (e.g., skin, muscle, bone marrow, spleen, liver, pancreas, lung, intestine, stomach, etc.) are best harvested via biopsy. The harvested cells can be dispersed or suspended using appropriate solutions. The harvested cells can be used immediately, or they can be stored long-term by freezing (cryopreservation), which allows for reuse after thawing. In this case, cells are typically frozen in 10% dimethyl sulfoxide (DMSO), 50% serum, 40% buffered medium, or some other such solutions commonly used in the art to preserve the cells at such freezing temperatures and thawed according to the methods commonly used in the art for thawing frozen cultured cells.

[0165] Forming a cell culture involves seeding the culture with a cell population. In some embodiments, the cell population is seeded at 5,000 cells / cm². 2 Up to 20,000 cells / cm 2 The density.

[0166] Any suitable cell culture medium can be used to maintain and passage the cultured cells and for IGFBP2 detection. Some non-limiting examples of culture media include Essential 8 (E8), MEM, DMEM, DMEM F12, RPMI 1640, SFM, HPLM, IMDM, Gibco Media 199, Ham's F-12, Ham's F10, and Medium 106. The culture medium may also contain supplements such as FBS, ROCK inhibitors, CEPT cocktail, antibiotics, or additional nutrients.

[0167] In some embodiments, the culture medium is E8 medium. In some embodiments, the E8 medium is further supplemented with the ROCK inhibitor Y-27632. In other embodiments, the E8 medium is further supplemented with a CEPT mixture.

[0168] The cells can be cultured in two-dimensional (2D) or three-dimensional (3D) cultures. 3D culture allows cells to grow and interact in all three dimensions.

[0169] In some implementations, the cells are cultured in 2D culture. 2D culture typically involves growing cells as a monolayer on a flat surface.

[0170] In other embodiments, the cells are cultured in 3D culture. 3D culture typically involves growing cells in a manner that allows them to grow and interact in all three dimensions, for example, by culturing them on non-adhesive surfaces and / or bioreactors.

[0171] In some embodiments, the 3D culture may utilize scaffolds that support and guide cell growth. In some embodiments, the scaffold is a hydrogel-based scaffold. In other embodiments, the 3D culture is performed under conditions in which the cells themselves form clusters of spherical bodies. Clusters or spherical bodies can be generated when cells are cultured on low-adhesion culture plates or micropatterned surfaces that induce cell clumping and extracellular matrix formation. Thus, in some embodiments, the term "3D culture," as used herein, encompasses 2D culture methods on low-adhesion materials that result in the formation of cell clumps (aggregates), including spherical bodies, in a suspension.

[0172] Cells in the culture can be suspended in the culture medium or adhered to the surface of a suitable cell culture vessel. Suitable cell culture vessels and systems include, but are not limited to, cell culture trays, flasks, plates, tubes, slides, cell factories, and bioreactors.

[0173] In some implementations, the cell culture is an adherent culture.

[0174] In other embodiments, the cell culture is a cell culture suspension.

[0175] In some implementations, the cell culture is in a bioreactor.

[0176] In some implementations, the cell culture is in a roller flask.

[0177] 6.4.1. Pluripotent stem cells (PSCs) Stem cells are the starting point for potentially generating large numbers of specific cell types that can be used in regenerative medicine for patients with many different diseases.

[0178] In some embodiments, the methods of this disclosure are used to detect the concentration of IGFBP2 in a culture medium sample of cultured stem cells.

[0179] In some implementations, the stem cells are pluripotent stem cells (PSCs), such as induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs).

[0180] In some implementations, the cells are iPSCs.

[0181] In some implementations, iPSCs are cultured by seeding preserved (e.g., cryopreserved) iPSCs onto suitable cell culture dishes.

[0182] In other embodiments, iPSCs are generated by methods including: (a) dedifferentiating adult cells; (b) introducing one or more nucleic acids encoding Yamanaka factors into adult cells; and (c) culturing adult cells under conditions expressing Yamanaka factors. Yamanaka factors are original factors discovered capable of reprogramming adult mammalian cells into iPSCs and include OCT4, KLF4, SOX2, and c-MYC. In some embodiments, the nucleic acids encode at least two, at least three, or all four of OCT4, KLF4, SOX2, and c-MYC. The nucleic acids introduced into the adult cells may include additional reprogramming factors (e.g., one or more of NANOG, Lin28, GLIS1, and BCL-XL).

[0183] In some implementations, the methods of this disclosure are used to determine the IGFBP2 concentration in PSC cell cultures before PSCs differentiate into other cells.

[0184] In some implementations, PSCs derived from the PSC cell culture are differentiated if the final concentration of IGFBP2 in the cell culture medium exceeds a threshold amount. The term "threshold amount" is used interchangeably with the term "threshold level" herein.

[0185] In some implementations, PSCs derived from the PSC cell culture are differentiated if the final concentration of IGFBP2 in the cell culture medium is within the target range.

[0186] In some implementations, the target range is from 50 ng / ml to 200 ng / ml.

[0187] In some implementations, PSCs derived from the PSC cell culture differentiate into dopaminergic neurons.

[0188] 6.4.2. PSC-derived cells The method disclosed herein can be used to detect the concentration of IGFBP2 in cell culture medium samples containing PSC-derived cells or cells that have undergone differentiation from PSCs into another cell type.

[0189] In some implementations, the concentration of IGFBP2 is measured once or multiple times during the first week or first month after PSC differentiation into different cell types (such as dopaminergic (DA) neurons). In some implementations, the concentration of IGFBP2 in the culture is measured at least once, at least twice, or at least three times during the first three, four, or five days after PSC differentiation into another cell type.

[0190] In some embodiments, the cells are undergoing differentiation from PSCs (or have already differentiated from PSCs) into lineages of endoderm (e.g., lung, thyroid, or pancreatic cells or their progenitors), ectoderm (e.g., skin, neurons, or pigment cells or their progenitors), and mesoderm (e.g., cardiomyocytes, skeletal muscle cells, erythrocytes, smooth muscle cells or their progenitors or precursors).

[0191] In some embodiments, the cells are undergoing differentiation from (or have already differentiated from) PSCs into neural lineage cells, such as neural crest cells, astrocytes, dopaminergic neuron progenitor cells, dopaminergic (DA) neurons, midbrain dopaminergic neuron progenitor cells, midbrain dopaminergic neurons, real midbrain dopaminergic (DA) neurons, dopaminergic neuron precursor cells, lamina midbrain progenitor cells, or lamina midbrain DA neurons.

[0192] In some implementations, the cells are undergoing differentiation from PSCs (or have already differentiated from PSCs) into dopaminergic (DA) neurons. Differentiation protocols can be used to differentiate PSCs into DA neurons, for example, according to Piao... et al. The contents of the embodiments described in PCT Publications WO 2016 / 196661 A1, WO 2010 / 096496 A2, WO 2013 / 067362A1, WO 2021 / 042027 A1, WO 2021 / 203009A1 and / or U.S. Patent No. 10,711,243 are incorporated herein by reference in their entirety.

[0193] In some implementations, the cells are undergoing differentiation from PSCs (or have already differentiated from PSCs) into oligodendrocyte progenitor cells or oligodendrocytes.

[0194] In some implementations, the cells are undergoing differentiation from (or have already differentiated from) PSCs into cells of the visual system, such as photoreceptor cells, photoreceptor precursor cells, retinal pigment epithelial cells, neural retinal cells, or neural retinal progenitor cells.

[0195] In some implementations, the cells are undergoing differentiation from PSCs (or have already differentiated from PSCs) into microglia or microglial progenitor cells.

[0196] In some implementations, the cells are undergoing differentiation from PSCs (or have already differentiated from PSCs) into human immune cells, such as macrophages, T cells, myeloid cells, dendritic cells, or T cells expressing chimeric antigen receptors (CARs) or recombinant TCRs.

[0197] In some implementations, the cells are undergoing differentiation from PSCs (or have already differentiated from PSCs) into intestinal progenitor cells or intestinal cells.

[0198] In some embodiments, the cells are undergoing differentiation from PSCs (or have already differentiated from PSCs) into cells of the human metabolic system, such as hepatocytes, bile duct cells, or pancreatic β cells. In some embodiments, the cells are undergoing differentiation from PSCs (or have already differentiated from PSCs) into cardiomyocytes (CM). In some embodiments, the cells are cultured cardiomyocytes. In some embodiments, the cells are cardiomyocytes undergoing maturation. In some embodiments, the concentration of IGFBP2 is detected once or multiple times to assess the maturation of cells differentiated from PSCs (e.g., cardiomyocytes).

[0199] 6.5. Application of IGFBP2 Measurement The IGFBP2 assay of this disclosure allows for the determination of IGFBP2 concentration in cell culture media. The method described in this disclosure for detecting IGFBP2 concentration in culture medium samples has a variety of applications.

[0200] The IGFBP2 assay of this disclosure can be used to estimate the number of cells in a cell culture, as described in Section 6.5.2. For example, the cell culture may be a cell culture containing PSCs, cells differentiated from PSCs, or cells undergoing dedifferentiation (e.g., to prepare PSCs). In some embodiments, the cell culture contains PSCs. In some embodiments, the cell culture contains cells differentiated from PSCs. In some embodiments, the cell culture contains cells that have undergone dedifferentiation into PSCs. In some embodiments, the cell culture contains cells cultured for cell maintenance (e.g., without change from one cell type to another).

[0201] The IGFBP2 assay of this disclosure can also be used to identify cell lines suitable for producing secreted peptides, as described in Section 6.5.3.

[0202] Furthermore, the IGFBP2 assay of this disclosure can be used as a standardized marker, as an alternative to housekeeping molecules, for standardization of detection in live cells, as described in Section 6.5.4.

[0203] The IGFBP2 assay of this disclosure can also be used to assess the health of cells in cell cultures, as described in Section 6.5.5.

[0204] Another application of the IGFBP2 assay of this disclosure is to identify and select improved cell culture parameters and / or optimize cell culture methods, as described in Section 6.5.6.

[0205] Another application of the IGFBP2 assay of this disclosure is to evaluate cell cultures containing cells that have undergone maturation, as described in Section 6.5.7.

[0206] 6.5.1. Cell line evaluation The methods disclosed herein can be used to evaluate cell populations (e.g., samples or aliquots of cells from a cell line). In some embodiments, the methods include evaluating cell populations, such as samples or aliquots of cells from a cell line, to determine a target IGFBP2 concentration range. Establishing a target IGFBP2 concentration range can serve as a benchmark for future culturing samples or aliquots of cells from a cell line and can be used for applications such as: cell number estimation (e.g., as described in Section 6.5.2), identification of cells suitable for producing secreted peptides (e.g., as described in Section 6.5.3), standardization of outputs from different batches of experiments (e.g., as described in Section 6.5.4), assessment of cell health (e.g., as described in Section 6.5.5), and testing cell culture parameters (e.g., as described in Section 6.5.6).

[0207] Establishing a target range for IGFBP2 concentration may involve culturing cells and evaluating IGFBP2 at different points in the culture, such as before feeding and / or after cell recovery from division. IGFBP2 measurements can be compared to similar measurements from another cell line (e.g., another cell line of the same type or historical data for the same cell line) and / or with one or more known markers of cell health, viability, and / or (for PSCs) differentiation potential. Such markers may include cell count, cell density, cell fusion, cell metabolism, ATP production and protease activity, and various recognized markers of secretion or cell health and / or death, such as lactate dehydrogenase (LDH) and secreted DNA. The target IGFBP2 concentration range can be determined based on its correlation with one or more such known IGFBP2 benchmarks and / or one or more known markers of cell health, viability, and / or differentiation potential.

[0208] For example, in some embodiments, cells (e.g., PSCs, such as those described in Section 6.4.1) are cultured and IGFBP2 concentration is detected as described in Section 6.3. One or more markers of cell health and / or viability are detected. IGFBP2 concentration is correlated with markers of cell health and / or viability to determine a target range for IGFBP2. This target range can then be used with the same type of cells for various applications, such as those described herein.

[0209] Exemplary target ranges for different cell types and cell culture containers are shown below: For a given cell type and culture conditions (e.g., container type) as described in this article, additional target ranges can be determined.

[0210] 6.5.2. Cell Number Estimation The methods disclosed herein can be used to estimate the number of cells in a culture, wherein the concentration of IGFBP2 in the culture medium indicates the number of cells in the cell culture. Cell count detection can be used to ensure consistency in cell storage, such as storing a consistent number of cells per vial.

[0211] In some implementations, one or more (or all) of an initial detection step, one or more subsequent detection steps (if performed), and / or a final detection step (if performed) are performed such that the detection indicates the number of cells in the cell culture.

[0212] Using IGFBP2 assays to estimate the number of cells in a cell culture can be used, but is not limited to, monitoring cell proliferation, testing (e.g., optimizing) cell culture conditions (e.g., by changing cell culture parameters and assessing their impact on IGFBP2 production), assays based on prepared cells, and processing said cells for downstream use. The number of cells in said cell culture can be estimated based on the concentration of IGFBP2 in said cell culture.

[0213] After estimating the number of cells in the culture using a final detection step, the cells can be further processed, wherein the further processing of the cell culture includes: (a) Passaging cells in the cell culture (or the whole cell culture); (b) Preserving cells from the cell culture (or the whole cell culture); (c) Disrupt the cells in the cell culture (or the entire cell culture); (d) If the cell culture contains PSCs, then differentiate the PSCs in the PSC cell culture (or the entire PSC cell culture); or (e) Any combination of one, two, three, or all four items from (a)-(d).

[0214] In some implementations, the cell culture is passaged if the final concentration of IGFBP2 is above a threshold level.

[0215] In some embodiments, the cell culture is passaged if the final IGFBP2 concentration is within the target range. In some embodiments, the target range is based on historical controls, such as previously determined ranges for the cell type or cell line, as described in Section 6.5.1. In some embodiments, such as when the cells are PSCs, the target range is 50 ng / ml to 200 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 250 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 300 ng / ml.

[0216] In some embodiments, the cell culture is preserved if the final IGFBP2 concentration is above a threshold level. In some embodiments, such as when the cells are PSCs, the threshold level is 150 ng / ml.

[0217] In some embodiments, the cell culture is preserved if the final IGFBP2 concentration is within the target range. In some embodiments, the target range is based on historical controls, such as previously determined ranges for the cell type or cell line, as described in Section 6.5.1. In some embodiments, such as when the cells are PSCs, the target range is 50 ng / ml to 200 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 250 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 300 ng / ml.

[0218] In some implementations, cell culture is terminated (e.g., by disrupting or discarding the cell culture) if the final IGFBP2 concentration is below a threshold level. In some implementations, such as when the cells are PSCs, the threshold level is 150 ng / ml.

[0219] In some embodiments, the cell culture is destroyed if the final concentration of IGFBP2 is below a threshold level. In some embodiments, such as when the cells are PSCs, the threshold level is 150 ng / ml.

[0220] In some embodiments, if the final IGFBP2 concentration is outside the target range, the cell culture is terminated (e.g., by destroying or discarding the cell culture). In some embodiments, if the final IGFBP2 concentration is outside the target range, the cell culture is destroyed. In some embodiments, the target range is based on historical controls, such as previously determined ranges for the cell type or cell line, as described in Section 6.5.1. In some embodiments, such as when the cells are PSCs, the target range is 50 ng / ml to 200 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 250 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 300 ng / ml.

[0221] In some embodiments, PSCs derived from the PSC cell culture are differentiated if the final concentration of IGFBP2 in the cell culture medium exceeds a threshold amount. In some embodiments, such as when the cells are PSCs, the threshold amount is 150 ng / ml.

[0222] In some embodiments, PSCs derived from the PSC cell culture differentiate if the final concentration of IGFBP2 in the cell culture medium is within a target range. In some embodiments, the target range is based on historical controls, such as previously determined ranges for the cell type or cell line, as described in Section 6.5.1. In some embodiments, such as when the cells are PSCs, the target range is 50 ng / ml to 200 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 250 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 300 ng / ml.

[0223] 6.5.3. Cells that produce secretory molecules Cultured cells can be used to produce secreted molecules, such as secreted peptides or polypeptides. IGFBP2 assays can be used to identify cell lines suitable for producing secreted polypeptides by simultaneously measuring IGFBP2 in cell cultures of the cell line and detecting the concentration of secreted polypeptides in the same cell culture.

[0224] In some embodiments, identifying a cell line suitable for producing the secreted peptide includes: (i) performing an IGFBP2 assay as described in Section 6.3; and (ii) simultaneously detecting the concentration of the secreted peptide in the cell culture, wherein the concentration of the secreted peptide is detected by an immunoassay. As used herein, reference to “simultaneous detection of the concentration of the secreted peptide” means detection of the concentration of the secreted peptide in the same sample of the cell culture medium on which the IGFBP2 assay is performed, or in a separate sample of the cell culture medium on which the IGFBP2 assay is performed, within one hour (optionally within half an hour, fifteen minutes, or five minutes).

[0225] In some embodiments, a concentration of secretory peptides above a threshold amount relative to IGFBP2 indicates that the cell line is suitable for producing secretory peptides, while a concentration of secretory peptides below a threshold amount relative to IGFBP2 indicates that the cell line is not suitable for producing secretory peptides.

[0226] The secreted polypeptide can be expressed endogenously or recombinantly in the cell line.

[0227] In some implementations, the secreted peptide is expressed endogenously in the cell line.

[0228] In other embodiments, the secreted peptide is recombinantly expressed in the cell line.

[0229] The concentrations of IGFBP2 and secreted peptides in cell cultures can be simultaneously detected using any type of secreted protein, peptide, and polypeptide, including but not limited to growth factors, interleukins, chemokines, interferons, lymphokines, hormones, and neurotransmitters.

[0230] Non-limiting examples of secreted proteins, peptides, and polypeptides include interleukins (e.g., interleukin-12 (IL-12), IL-1α, IL-1β, IL-1R4 (ST2), IL-2, IL-2R, IL-3, IL-3Rα, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-8RB, IL-11, IL-12p40, IL-12p70, IL-13, IL-13...). R1, IL-13R2, IL-15, IL-15Rα, IL-16, IL-17, IL-17C, IL-17E, IL-17F, IL-17R, IL-18, IL-18BPa, IL-18Rα, IL-20, IL-23, IL-27, IL-28, IL-31 and IL-33), growth factors (e.g., angiopoietin, angiopoietin-1, angiopoietin-2, bNGF, VEGF-A, VEGF-A, etc.). C, VEGF-D, VEGF-R1, VEGF-R2, VEGF-R3, G-CSF, GM-CSF, P1GF, P1GF-2, BDNF, BMP4, EGF, FGF-1, FGF-2, FGF-7, FGF-21, Follistatin, GDF-15, HB-EGF, HGF, LAP, NT-3, NT-4, TGF-α, TGF-β and TGF-β3, cytokines and Chemokines (e.g., GCP-2, GM-CSF, PDGF-AA, PDGF-BB, PDGF-AB, SDF-1, 6-Ckine, BLC, BRAK, CD186, ENA-78, eosinophil chemokine-1, eosinophil chemokine-2, eosinophil chemokine-3, MCP-1, MCP-2, MCP-3, MCP-4, MIP-1γ, MIP-1α, MIP-1) β, MIP-1δ, MIP-3α, MIP-3β, MPIF-1, PARC, PAI-1, IP-10, I-TAC, LIF, LIX, M-CSF, MIF, MIG, GDF-15, GM-CSF, GRO, HCC-4, PF4, RANTES, Resistin, SCF, SCYB16, TARC, TSLP, TNF-α, TRAIL-R4, Activin A, Amphiregulin, Axl and I-309, RANTES and CXCR4), interferons (e.g., IFN-α, IFN-β, and IFN-γ), differentiation markers (e.g., TFF3, PTN, and LGI1), and other secreted proteins, peptides, and polypeptides (e.g.,The following substances were detected: cathepsin S, galectin-7, Tie2, EpCAM, LRP6, TACI, TNF-R1, TREM-1, galectin-7, Gash, IGFBP-1, IGFBP-3, IGFBP-6, MADCam-1, NGF R, NrCAM, TRAIL-R4, ADAMTS1, MMP-9, pro-MMP9, RANK, and RANKL.

[0231] In some embodiments, the secreted polypeptide is interleukin-12 (IL-12). Human IL-12 is a dimer composed of p40 and p35 subunits. The full-length human p40 has the following amino acid sequence, corresponding to Uniprot identification number P43432, as shown below, with the signal sequence underlined: MCHQQLVISWFSLVFLASPLVA IWELKKDVYVVELDWYPDAPGEMVVLTC DTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHS LLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTIST DLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVIC RKNASISVRAQDRYYSSSWSEWASVPCS (SEQ ID NO:14) Full-length human p35 has the following amino acid sequence, corresponding to Uniprot identification number P29459, as shown below, with the signal sequence underlined: MCPARSLLLVATLVLLDHLSLA RNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS(SEQ ID NO:15) In some embodiments, IL-12 and IGFBP2 concentrations are detected in DA neuronal cell cultures. IL-12 concentrations can be detected using the methods for IGFBP2 described in Section 6.3, for example, using an anti-IL12 antibody described in U.S. Patent No. 11,197,913, the disclosure of which is incorporated herein by reference.

[0232] In some embodiments, the secreted polypeptide is trefoil factor 3 (TFF3). Full-length human TFF3 is 80 amino acids long and has the following amino acid sequence, corresponding to Uniprot identification number Q07654, as shown below, with the signal sequence underlined: MAARALCMLGLVLALLSSSSA EEYVGLSANQCAVPAKDRVDCGYPHVTPKECNRGCCFDSRIPGVPWCFKPLQEAECTF (SEQ ID NO:12) In some embodiments, the concentrations of TFF3 and IGFBP2 are detected in DA neuronal cell cultures. The TFF3 concentration can be detected using the methods for IGFBP2 described in Section 6.3, for example, using anti-TFF3 antibodies as described in PCT Publication No. WO 2005 / 013802A2 and U.S. Patent No. 10,551,392, the disclosures of which are incorporated herein by reference.

[0233] In some embodiments, the secreted polypeptide is a pleiotropic growth factor (PTN). Full-length human PTN is 168 amino acids long and has the following amino acid sequence, corresponding to Uniprot identification number P21246, as shown below, with the signal sequence underlined: MQAQQYQQQRRKFAAAFLAFIFILAAVDTAEA GKKEKPEKKVKKSDCGEWQWSVCVPTSGDCGLGTREGTRTGAECKQTMKTQRCKIPCNWKKQFGAECKYQFQAWGECDLNTALKTRTGSLKRALHNAECQKTVTISKPCGKLTKPKPQAESKKKKKEGKKQEKMLD (SEQ ID NO:13) In some embodiments, PTN and IGFBP2 concentrations are detected in DA neuronal cell cultures. PTN concentration can be detected using the methods for IGFBP2 described in Section 6.3, for example using antiPTN antibodies as described in U.S. Publication No. 2014 / 0294845 A1 and U.S. Patent No. 7,608,264, the disclosures of which are incorporated herein by reference.

[0234] In some embodiments, the secreted polypeptide is leucine-rich glioma inactivation 1 protein (LGI1). Full-length human LGI1 is 557 amino acids long and has the following amino acid sequence, corresponding to Uniprot identification number O95970, as shown below, with the signal sequence underlined: MESERSKRMGNACIPLKRIAYFLCLLSALLLTEG KKPAKPKCPAVCTCTKDNALCENARSIPRTVPPDVISLSFVRSGFTEISEGSFLFTPSLQLLLFTSNSFDVISDDAFIGLPHLEYLFIENNNIKSISRHTFRGLKSLIHLSLANNNLQTLPKDIFKGLDS LTNVDLLRGNSFNCDCKLKWLVEWLGHTNATVEDIYCEGPPEYKKRKINSLSSKDFDCIITEFAKSQDLPYQSLSIDTFSYLNDEYVVIAQPFTGKCIFLEWDHVEKTFRNYDNITGTSTVVCKPIVIETQL YVIVAQLFGGSHIYKRDSFANKFIKIQDIEILKIRKPNDIETFKIENNWYFVVADSSKAGFTTIYKWNGNGFYSHQSLHAWYRDTDVEYLEIVRTPQTLRTPHLILSSSSQRPVIYQWNKATQLFTNQTDI PNMEDVYAVKHFSVKGDVYICLTRFIGDSKVMKWGGSSFQDIQRMPSRGSMVFQPLQINNYQYAILGSDYSFTQVYNWDAEKAKFVKFQELNVQAPRSFTHVSINKRNFLFASSFKGNTQIYKHVIVDLSA (SEQ ID NO:16) In some embodiments, LGI1 and IGFBP2 concentrations are detected in DA neuronal cell cultures. LGI1 concentration can be detected using the methods for IGFBP2 described in Section 4.3, for example using an anti-LGI antibody as described in U.S. Patent No. 9,250,250, the disclosure of which is incorporated herein by reference.

[0235] 6.5.4. Standardize the output of different batches of experiments Cell behavior can vary between different batches of experiments. Therefore, outputs from different batches of cell culture experiments cannot be compared or analyzed together unless these outputs are standardized by controlling for their expression (e.g., housekeeping molecule expression). Assessing housekeeping molecules requires manipulating cells, such as preparing cell extracts, and this is not easily accomplished without damaging cells in live cultures. Therefore, using IGFBP2 as a standardized marker across different batches of cell culture experiments can serve as an alternative to housekeeping molecules for standardized detection in live cells.

[0236] Methods for controlling cell behavior in cell culture experiments may include: (i) studying the cell culture; and (ii) performing an IGFBP2 assay as described in Section 6.3, wherein the cell culture is considered to be behaving normally if the IGFBP concentration in the cell culture is within a target range.

[0237] In some embodiments, the target range is based on historical controls, such as previously determined ranges for the cell type or cell line, as described in Section 6.5.1. In some embodiments, such as when the cells are PSCs, the target range is 50 ng / ml to 200 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 250 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 300 ng / ml. In some embodiments, such as when the cells are cardiomyocytes, the target range is 0 ng / ml to 20 ng / ml. In some embodiments, such as when the cells are DA neurons, the target range is 0 ng / ml to 20 ng / ml.

[0238] Methods for controlling cell behavior can be used in cell culture experiments containing the same cell line under different conditions. Non-limiting examples of cell culture experiments containing the same cell line under different conditions include experiments with the same cell line performed at different times; experiments performed in parallel with the same cell line but in culture vessels of different types or sizes; experiments performed in parallel with the same cell line but with a new batch of culture medium and / or supplements; and experiments performed by different experimenters using the same cell line.

[0239] Methods for controlling cell behavior can also be used in cell culture experiments that involve culturing different cell lines under the same conditions. The different cell lines in such experiments may include one or more test cell lines and one or more control cell lines, wherein the one or more control cell lines may include one or more positive control cell lines and one or more negative control cell lines.

[0240] In some implementations, the cell culture experiment involves culturing the same cell line under different conditions.

[0241] In some embodiments, the cell culture experiment includes culturing different cell lines under the same conditions, wherein the different cell lines include one or more test cell lines and one or more control cell lines.

[0242] In some embodiments, one or more control cell lines include a positive control cell line and / or a negative control cell line.

[0243] In some implementations, one or more control cell lines include a positive control cell line.

[0244] In some implementations, one or more control cell lines include a negative control cell line.

[0245] In some implementations, one or more control cell lines include both positive control cell lines and negative control cell lines.

[0246] In some implementation schemes, different cell lines are cultured simultaneously.

[0247] 6.5.5. Assessment of Cell Health The IGFBP2 assay disclosed herein can be used to assess the health of cultured cells in a test cell line, wherein the test cell line is considered healthy if the IGFBP2 concentration is within a target range.

[0248] Methods for assessing the health of a test cell line may include: (i) seeding the test cell line at a low density into a cell culture; and (ii) performing an IGFBP2 assay as described in Section 6.3, wherein the target range of IGFBP2 can be determined by: (a) seeding one or more control cell lines in parallel into a cell culture at a low density; and (b) performing an IGFBP2 assay as described in Section 6.3.

[0249] In some implementations, assessing the health of the test cell line includes: (i) seeding the test cell line at a low density into a cell culture; (ii) performing an IGFBP2 assay as described in Section 6.3; and (iii) comparing the IGFBP2 concentration to a target range.

[0250] In some implementations, the IGFBP2 target range is determined by: (i) seeding one or more control cell lines in parallel into a cell culture at a low density; and (ii) performing an IGFBP2 assay as described in Section 6.3.

[0251] In some implementations, assessing the health of the test cell line includes: (i) seeding the test cell line into a cell culture at a low density; (ii) performing an IGFBP2 assay as described in Section 6.3 and determining the target range of IGFBP2 by: (a) seeding one or more control cell lines in parallel into a cell culture at a low density; and (b) performing an IGFBP2 assay as described in Section 6.3, wherein the seeding density of the test cell line is the same as that of the control cell line.

[0252] In some embodiments, the control cell line comprises a known healthy positive cell line, wherein the test cell line is considered healthy if the IGFBP2 concentration in the test cell culture is at least 75% of the IGFBP2 concentration in the positive control cell culture.

[0253] In some embodiments, the control cell line includes a negative control cell line known to be unhealthy, wherein the test cell line is considered healthy if the IGFBP2 concentration in the test cell culture exceeds the IGFBP2 concentration in the negative control cell culture.

[0254] In some embodiments, the control cell line comprises a negative control cell line known to be unhealthy and a positive control cell line known to be healthy, wherein the test cell line is considered healthy if the IGFBP2 concentration in the test cell culture (i) exceeds the IGFBP2 concentration of the negative control cell culture and (ii) is at least 75% of the IGFBP2 concentration of the positive control cell culture.

[0255] In some embodiments, the target range is based on historical controls, such as previously determined ranges for the cell type or cell line, as described in Section 6.5.1. In some embodiments, such as when the cells are PSCs, the target range is 50 ng / ml to 200 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 250 ng / ml. In some embodiments, such as when the cells are PSCs, the target range is 150 ng / ml to 300 ng / ml. In some embodiments, such as when the cells are cardiomyocytes, the target range is 0 ng / ml to 20 ng / ml. In some embodiments, such as when the cells are DA neurons, the target range is 0 ng / ml to 20 ng / ml.

[0256] 6.5.6. Testing Cell Culture Parameters The IGFBP2 assays disclosed herein can be used to test cell culture workflows and parameters. Without being bound by theory, as described herein, the IGFBP2 concentration in the cell culture medium is understood as an indicator of cell culture health, and therefore, changes in IGFBP2 concentration in response to changes in cell culture parameters are considered to indicate whether changes in cell culture parameters (e.g., cell culture medium, seeding density, medium, medium supplement, culture time, division density, etc.) or these parameters have a positive impact on cell growth and / or viability.

[0257] Methods for testing cell culture parameters may include (i) culturing cell lines under a first set of parameters and performing IGFBP2 assays as described in Section 6.3, and (ii) comparing the IGFBP2 values ​​with IGFBP2 values ​​of cell lines cultured under a second set of parameters that differ from the first set of parameters by at least one parameter (e.g., a single parameter), and performing IGFBP2 assays as described in Section 6.3 under the second set of parameters. The culturing of cell lines under the first set of parameters under the second set of parameters may be performed in parallel (e.g., simultaneously) or sequentially (e.g., sequentially).

[0258] Therefore, in some embodiments, the method for testing cell culture parameters may include (i) culturing the cell line under a first set of parameters and performing an IGFBP2 assay as described in Section 6.3, (ii) culturing the cell line under a second set of parameters that differ from the first set of parameters by at least one parameter (e.g., a single parameter) and performing an IGFBP2 assay as described in Section 6.3, and (iii) comparing the IGFBP2 detection values ​​from the two sets of parameters, e.g., to determine whether the different parameters contribute to cell culture health.

[0259] In some implementations, continuous culture can be pre-cultured and tested to determine the target IGFBP2 concentration range (e.g., as described in Section 6.5.1).

[0260] In some implementations, methods for testing cell culture parameters include evaluating the use of a second culture medium different from the first culture medium by: (i) culturing a cell line using the first culture medium; (ii) culturing the same cell line (in parallel or at separate times) using a second, different culture medium; and (b) performing an IGFBP2 assay on both cell cultures as described in Section 6.3.

[0261] Various cell culture media are recognized in the art and can be evaluated using the disclosed methods. Non-limiting examples of culture media that can be evaluated include Essential 8 (E8), MEM, DMEM, DMEM F12, RPMI 1640, SFM, HPLM, IMDM, Gibco Medium 199, Ham's F-12, Ham's F10, and Medium 106.

[0262] In some implementations, methods for testing cell culture parameters include evaluating the use of a specific cell culture medium supplement by: (i) culturing a cell line in the absence of the supplement; (ii) culturing the same cell line (in parallel or at separate times) in the presence of the supplement; and (b) performing an IGFBP2 assay on both cell cultures as described in Section 6.3.

[0263] Various cell culture supplements are well-established in the art and can be evaluated using the disclosed methods. Non-limiting examples of cell culture supplements that can be evaluated include FBS, ROCK inhibitors (e.g., Y-27632), CEPT mixtures, antibiotics, and nutrients.

[0264] In some embodiments, methods for testing cell culture parameters include evaluating the use of a specific cell culture vessel (e.g., cell culture dish, multilayer cell factory, etc.) by: (i) culturing a cell line in a first cell culture vessel; (ii) culturing the same cell line (in parallel or at separate times) in a second, different cell culture vessel; and (b) performing an IGFBP2 assay on both cell cultures as described in Section 6.3. In some embodiments, methods for testing cell culture parameters include evaluating the use of a specific set of cell culture vessel conditions (e.g., substrate coating temperature and / or duration) by: (i) culturing a cell line in a first set of conditions (e.g., a vessel coated with a substrate at a first temperature and / or a first duration); (ii) culturing the same cell line (in parallel or at separate times) in a second, different set of conditions (e.g., a vessel coated with a substrate at a second temperature and / or a second duration); and (b) performing an IGFBP2 assay on both cell cultures as described in Section 6.3.

[0265] In some implementations, the type of coating matrix is ​​evaluated. Some non-limiting examples of culture vessel coating matrices are phospholipids, streptavidin, antibodies, collagen, cadherin, laminin, hydrin, poly-d-lysine (PDL), nickel chelates, protein A, WGA (wheat germ lectin), and hydrogels.

[0266] In some implementations, the duration and / or temperature of the coating are evaluated.

[0267] In some implementations, the culture container is coated with a coating matrix for 0.5 hours, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 1 day, 2 days, 3 days, or 4 days or longer.

[0268] In some embodiments, the culture container is coated with a coating matrix for 1 hour. In other embodiments, the culture container is coated with a coating matrix overnight (e.g., between 16 and 20 hours).

[0269] In some embodiments, the culture container is coated with a coating matrix at room temperature (e.g., between 20°C and 25°C). In some other embodiments, the culture container is coated with a coating matrix at 4°C or about 4°C (e.g., between 3°C and 5°C).

[0270] In some embodiments, methods for testing cell culture parameters include assessing seeding density and / or cell confluence maturity by: (i) culturing cell lines at a first density; (ii) culturing the same cell lines (in parallel or at separate times) at a second, different density (e.g., higher or lower density); and (b) performing IGFBP2 assays on both cell cultures as described in Section 6.3.

[0271] The testing method may further include determining whether there is a difference in IGFBP2 concentration between a first set of parameters and a second set of parameters. If no such difference exists, the second set of parameters can be considered not to improve cell line health. If such a difference does exist, the second set of parameters can be considered to improve cell line health if the IGFBP2 concentration detected from the first set of parameters is below the target range while the second set of parameters is within the target range. In other words, IGFBP2 concentration can be used to identify whether a specific cell culture parameter or a set of parameters contributes to cell line health by identifying a set of parameters that brings IGFBP2 concentration into a desired target range (e.g., a pre-determined target range based on pre-detection of cells known to be healthy or having desired parameters, such as differentiation).

[0272] 6.5.7. Assessment of Cell Maturity The method disclosed herein can be used to assess the maturity of differentiated cells in a culture, wherein the concentration of IGFBP2 in the culture medium indicates the maturity status of the cells in the cell culture.

[0273] In some implementations, one or more (or all) of an initial detection step, one or more subsequent detection steps (if performed), and / or a final detection step (if performed) are performed such that the detection indicates the cell maturity in the cell culture.

[0274] After assessing the maturity of the cells in the culture using a final detection step, the cells can be further processed, wherein the further processing of the cell culture includes: (a) Passaging cells in the cell culture (or the whole cell culture); (b) Preserving cells from the cell culture (or the whole cell culture); (c) Disrupt the cells in the cell culture (or the entire cell culture); (e) Any combination of one, two, or all three items from (a)-(c).

[0275] In some embodiments, the cell culture is destroyed if the final concentration of IGFBP2 in the cell culture medium exceeds a threshold amount and / or is outside the target range. In some embodiments, the target range is based on historical controls, such as previously determined ranges for the cell type or cell line, as described in Section 6.5.1. In some embodiments, such as when the cells are cardiomyocytes, the threshold amount is 20 ng / ml. In some embodiments, such as when the cells are cardiomyocytes, the target range is 0 ng / ml to 20 ng / ml.

[0276] In some embodiments, the cell culture is preserved if the final IGFBP2 concentration is below a threshold level and / or within a target range. In some embodiments, the target range is based on historical controls, such as previously determined ranges for the cell type or cell line, as described in Section 6.5.1. In some embodiments, such as when the cells are cardiomyocytes, the threshold amount is 20 ng / ml. In some embodiments, such as when the cells are cardiomyocytes, the target range is 0 ng / ml to 20 ng / ml.

[0277] 7. Specific Implementation Plan The following specific implementation plan is used as an example to illustrate the content of this disclosure.

[0278] 1. A method comprising: (a) Detecting the initial concentration of insulin-like growth factor binding protein 2 (IGFBP2) in the culture medium of cell cultures (“Initial Detection Step”); (b) Optionally, detect at least one subsequent concentration of IGFBP2 in the culture medium of the cell culture (each “subsequent detection step”); and (c) Optionally, the final concentration of IGFBP2 level in the culture medium of the cell culture is detected (“Final Detection Step”).

[0279] 2. The method of implementation scheme 1, which includes performing step (b).

[0280] 3. The method of implementation scheme 2, wherein step (b) includes detecting multiple subsequent concentrations of IGFBP2 in the culture medium of the cell culture.

[0281] 4. Implement the method of Implementation 3, wherein step (b) is repeated once or twice a day for at least three days.

[0282] 5. Implement the method of Implementation 3, wherein step (b) is repeated once or twice a day for at least four days.

[0283] 6. Implement the method of Implementation 3, wherein step (b) is repeated once or twice a day for at least five days.

[0284] 7. The method of any one of implementation schemes 4 to 6, wherein step (b) is repeated daily until one or two days before the cell culture is passaged.

[0285] 8. Implement the method of any one of 3 to 7, wherein step (b) is repeated every other day for at least 6 days.

[0286] 9. Implement the method of any one of 3 to 7, wherein step (b) is repeated every other day for at least 8 days.

[0287] 10. The method of any one of implementations 3 to 7, wherein step (b) is repeated every other day for at least 10 days.

[0288] 11. Implement the method of any one of 3 to 7, wherein step (b) is repeated every other day for at least two weeks.

[0289] 12. Implement the method of any one of 3 to 7, wherein step (b) is repeated every other day for at least three weeks.

[0290] 13. The method of any one of implementations 8 to 12, wherein step (b) is repeated every other day for up to four weeks.

[0291] 14. The method of any one of embodiments 1 to 13, wherein each subsequent detection step is performed when the cell culture is not fed.

[0292] 15. The method of any one of embodiments 1 to 14, wherein the IGFBP2 concentration in the culture medium indicates the number of cells in the cell culture.

[0293] 16. The method of any one of embodiments 1 to 15, further comprising feeding the cell culture after one or more subsequent detection steps.

[0294] 17. The method of embodiment 16, further comprising feeding the cell culture after most of the subsequent detection steps.

[0295] 18. The method of embodiment 16 or embodiment 17, wherein the cell culture is fed daily.

[0296] 19. The method according to any one of embodiments 1 to 18, further comprising performing step (c).

[0297] 20. The method of implementation scheme 19, wherein the final detection step is performed when the cell culture is not replenished.

[0298] 21. A method according to any one of embodiments 1 to 20, wherein one or more (or all) of an initial detection step, one or more subsequent detection steps (if performed) and / or a final detection step (if performed) are performed such that the detection indicates the number of cells in the cell culture.

[0299] 22. A method according to any one of embodiments 1 to 21, wherein one or more (or all) of an initial detection step, one or more subsequent detection steps (if performed) and / or a final detection step (if performed) are performed such that the detection indicates the maturity of cells in the cell culture.

[0300] 23. The method of any one of embodiments 1 to 22, wherein when at least 12 hours have passed since the previous feeding, one or more (or all) of the initial detection step, one or more subsequent detection steps (if performed) and / or the final detection step (if performed) are performed.

[0301] 24. The method according to any one of embodiments 1 to 22, wherein each subsequent testing step is performed when at least 15 hours have passed since the previous feeding.

[0302] 25. The method according to any one of embodiments 1 to 22, wherein each subsequent testing step is performed when at least 18 hours have elapsed since the previous feeding.

[0303] 26. The method according to any one of embodiments 1 to 25, comprising step (c) and further comprising step (d), wherein step (d) comprises any combination of one, two, three, or all four of the following steps: (i) Disrupt the cells in the cell culture (or the entire cell culture); (ii) Passage the cells in the cell culture (or the whole cell culture); (iii) Preserving cells from the cell culture (or the whole cell culture); and (iv) If the cell culture contains pluripotent stem cells (PSCs), then differentiate the PSCs in the PSC cell culture (or the entire PSC cell culture).

[0304] 27. The method of embodiment 26, wherein step (d) comprises: destroying the cell culture if the final concentration (a) of IGFBP2 in the cell culture medium is below a threshold amount and / or (b) outside a target range.

[0305] 28. The method of embodiment 26, wherein step (d) comprises: passage cells in the cell culture (or the whole cell culture) if the final concentration (a) of IGFBP2 in the cell culture medium is above a threshold amount and / or (b) is within a target range.

[0306] 29. The method of embodiment 26 or embodiment 28, wherein step (d) comprises: preserving cells from the cell culture (or the whole cell culture) if the final concentration (a) of IGFBP2 in the cell culture medium is above a threshold amount and / or (b) is within a target range.

[0307] 30. The method of embodiment 26, wherein step (d) comprises: destroying the cell culture if the final concentration (a) of IGFBP2 in the cell culture medium is above a threshold amount and / or (b) is outside a target range.

[0308] 31. The method of embodiment 26, wherein step (d) comprises: preserving cells from the cell culture (or the whole cell culture) if the final concentration (a) of IGFBP2 in the cell culture medium is below a threshold amount and / or (b) is within a target range.

[0309] 32. The method of any one of embodiments 27 to 31, wherein the target range is from 50 ng / ml to 200 ng / ml.

[0310] 33. The method of any one of embodiments 1 to 32, wherein the detection step is performed via an immunoassay, optionally wherein the immunoassay is an enzyme-linked immunosorbent assay (ELISA), a fluorescence resonance energy transfer (FRET) assay, or a Western blot.

[0311] 34. The method of implementation scheme 33, wherein the immunoassay is an enzyme-linked immunosorbent assay (ELISA).

[0312] 35. The method of embodiment 33, wherein the immunoassay is a fluorescence resonance energy transfer (FRET) assay.

[0313] 36. The method of any one of embodiments 1 to 35, wherein the cell culture is a two-dimensional (2D) cell culture.

[0314] 37. The method of any one of embodiments 1 to 35, wherein the cell culture is a three-dimensional (3D) cell culture.

[0315] 38. The method of any one of embodiments 1 to 35, wherein the cell culture is an adherent culture.

[0316] 39. The method of any one of embodiments 1 to 35, wherein the cell culture is a suspension.

[0317] 40. The method of embodiment 39, wherein the culture is in a bioreactor.

[0318] 41. The method of any one of embodiments 1 to 40, further comprising forming the cell culture prior to step (a).

[0319] 42. The method of implementation 41, wherein forming the cell culture includes inoculating the culture with a cell population.

[0320] 43. The method of implementation scheme 42, wherein the population is seeded at 5,000 cells / cm². 2 Up to 20,000 cells / cm 2 The density.

[0321] 44. The method of any one of embodiments 1 to 43, wherein the cell culture comprises PSCs and / or cells that have undergone differentiation from PSCs into another cell type.

[0322] 45. The method of embodiment 43 or embodiment 44, wherein the cell culture is inoculated with a preserved (e.g., cryopreserved) population of PSCs.

[0323] 46. ​​The method of implementation scheme 44 or implementation scheme 45, wherein the PSC is an iPSC.

[0324] 47. The method of implementation scheme 46, wherein the iPSC is the product of processes including: (a) Dedifferentiated somatic cells; (b) Introducing one or more nucleic acids encoding the mountain factor into the adult cells; and (c) The adult cells are cultured under conditions expressing the Yamanaka factor to generate a population of iPSCs.

[0325] 48. The method of any one of embodiments 44 to 47, wherein step (d) (if present) comprises: differentiating PSCs from the PSC cell culture if the final concentration (a) of IGFBP2 in the cell culture medium is above a threshold amount and / or (b) is within a target range.

[0326] 49. The method of implementation scheme 48, wherein the target range is 150 ng / ml to 300 ng / ml.

[0327] 50. The method of implementation scheme 48, wherein the target range is 150 ng / ml to 250 ng / ml.

[0328] 51. The method of implementation scheme 48, wherein the target range is 50 ng / ml to 200 ng / ml.

[0329] 52. The method of any one of embodiments 44 to 51 further includes: detecting an additional concentration of IGFBP2 level in the culture medium of the cell culture prior to differentiating PSCs from the PSC cell culture.

[0330] 53. The method of any one of embodiments 44 to 52, further comprising: detecting an additional concentration of IGFBP2 level in the culture medium of the cell culture during the differentiation of PSCs derived from the PSC cell culture.

[0331] 54. The method according to any one of embodiments 44 to 53, further comprising: after differentiating PSCs from the PSC cell culture, detecting an additional concentration of IGFBP2 level in the culture medium of the cell culture.

[0332] 55. The method of any one of embodiments 48 to 54, wherein PSCs derived from said PSC cell cultures differentiate into dopaminergic neurons.

[0333] 56. The method of any one of embodiments 48 to 55, further comprising: repeating the method of any one of embodiments 1 to 43 during and / or after the differentiation period.

[0334] 57. The method of any one of embodiments 48 to 56, wherein the cell culture comprises PSCs that have undergone differentiation into dopaminergic neurons.

[0335] 58. The method of any one of embodiments 1 to 57, wherein the cell culture comprises dopaminergic neurons.

[0336] 59. The method of embodiment 58, wherein step (c) is performed at least 5 days after seeding the dopaminergic neurons or their precursors (e.g., PSCs).

[0337] 60. The method of embodiment 58, wherein step (c) is performed at least 6 days after seeding the dopaminergic neurons or their precursors (e.g., PSCs).

[0338] 61. The method of embodiment 58, wherein step (c) is performed at least 7 days after inoculation of the dopaminergic neuron or its precursor (e.g., PSC).

[0339] 62. The method of embodiment 58, wherein step (c) is performed at least 8 days after seeding the dopaminergic neurons or their precursors (e.g., PSCs).

[0340] 63. The method of embodiment 58, wherein step (c) is performed between 9 and 12 days after inoculation of the dopaminergic neurons or their precursors (e.g., PSCs).

[0341] 64. The method of embodiment 58, wherein step (c) is performed between 10 and 12 days after inoculation of the dopaminergic neurons or their precursors (e.g., PSCs).

[0342] 65. The method of embodiment 58, wherein step (c) is performed between 9 and 11 days after inoculation of the dopaminergic neurons or their precursors (e.g., PSCs).

[0343] 66. The method of embodiment 58, wherein step (c) is performed between 9 and 10 days after inoculation of the dopaminergic neurons or their precursors (e.g., PSCs).

[0344] 67. The method of embodiment 58, wherein step (c) is performed between 11 and 12 days after inoculation of the dopaminergic neurons or their precursors (e.g., PSCs).

[0345] 68. The method of embodiment 58, further comprising: harvesting the dopaminergic neurons if the final concentration of IGFBP2 in the cell culture medium (a) is above a threshold amount and / or (b) is within a target range.

[0346] 69. The method of embodiment 68, further comprising formulating the harvested dopaminergic neurons in a composition.

[0347] 70. The method of embodiment 69, wherein the composition is a pharmaceutical composition for treatment.

[0348] 71. The method of embodiment 58, further comprising: maintaining the dopaminergic neurons in the culture if the final concentration of IGFBP2 in the cell culture medium is (a) below a threshold amount and / or (b) outside a target range.

[0349] 72. The method of embodiment 71, further comprising: detecting an additional concentration of IGFBP2 levels in the culture medium of the dopaminergic neuron culture.

[0350] 73. The method of embodiment 72, wherein the additional concentration is detected at least 24 hours after the final concentration.

[0351] 74. The method of embodiment 72, wherein the additional concentration is detected at least 2 days after the final concentration.

[0352] 75. The method of embodiment 72, wherein the additional concentration is detected at least 3 days after the final concentration.

[0353] 76. The method of any one of embodiments 72 to 75, further comprising: terminating the cell culture (e.g., destroying or discarding the cell culture) if the additional concentration of IGFBP2 in the cell culture medium (a) is below a threshold amount and / or (b) is outside a target range.

[0354] 77. The method of any one of embodiments 72 to 75, further comprising: destroying the dopaminergic neurons if an additional concentration of IGFBP2 in the cell culture medium (a) is below a threshold amount and / or (b) is outside a target range.

[0355] 78. The method of embodiment 58, further comprising: terminating the cell culture (e.g., destroying or discarding the cell culture) if the final concentration of IGFBP2 in the cell culture medium (a) is below a threshold amount and / or (b) is outside a target range.

[0356] 79. The method of embodiment 58, further comprising: destroying the dopaminergic neurons if the final concentration of IGFBP2 in the cell culture medium (a) is below a threshold amount and / or (b) is outside a target range.

[0357] 80. The method of any one of embodiments 1 to 43, wherein the cell culture comprises cells that have undergone maturation.

[0358] 81. The method of embodiment 80, wherein the cell culture comprises mature cardiomyocytes.

[0359] 82. The method of embodiment 80 or embodiment 81, further comprising: terminating the cell culture (e.g., destroying or discarding the cell culture) if the final concentration of IGFBP2 in the cell culture medium (a) is above a threshold amount and / or (b) is outside a target range.

[0360] 83. The method of embodiment 80 or embodiment 81, wherein step (d) (if present) comprises: destroying the cell culture if the final concentration of IGFBP2 in the cell culture medium (a) is above a threshold amount and / or (b) is outside a target range.

[0361] 84. The method of embodiment 80 or embodiment 81, wherein step (d) (if present) comprises: preserving cells from the cell culture (or the whole cell culture) if the final concentration of IGFBP2 in the cell culture medium (a) is below a threshold amount and / or (b) is within a target range.

[0362] 85. The method of any one of embodiments 82 to 84, wherein the threshold amount is 20 ng / ml.

[0363] 86. The method of any one of embodiments 82 to 85, wherein the target range is from 0 ng / ml to 20 ng / ml.

[0364] 87. A method for identifying cell lines suitable for producing secretory polypeptides, comprising: (a) Detecting the IGFBP2 concentration in the cell culture of the cell line according to any one of embodiments 1 to 43; and (b) While detecting IGFBP2, the concentration of secreted peptides in the cell culture was also detected.

[0365] 88. The method of embodiment 87, wherein simultaneously detecting the concentrations of IGFBP2 and secreted peptides in the cell culture comprises: detecting the concentration of secreted peptides in the same sample of the cell culture supernatant.

[0366] 89. The method of embodiment 87, wherein the simultaneous detection of the concentrations of IGFBP2 and secreted peptides in the cell culture comprises: detecting the concentration of secreted peptides in different samples of the cell culture supernatant obtained within one hour (optionally within half an hour, fifteen minutes, or five minutes) of detecting IGFBP2.

[0367] 90. The method of any one of embodiments 87 to 89, wherein the concentration of the secreted peptide is detected by immunoassay.

[0368] 91. The method of any one of embodiments 87 to 90, wherein the secreted polypeptide is interleukin-12, Tff3, PTN, LGI1, or any combination of two or more of the foregoing.

[0369] 92. The method of any one of embodiments 87 to 91, wherein a concentration of the secretory peptide above a threshold amount relative to the amount of IGFBP2 indicates that the cell line is suitable for producing the secretory peptide.

[0370] 93. The method of any one of embodiments 87 to 92, wherein the secreted polypeptide is recombinantly expressed in the cell line.

[0371] 94. The method of any one of embodiments 87 to 92, wherein the secreted polypeptide is endogenously expressed in the cell line.

[0372] 95. The method of any one of embodiments 87 to 94, wherein the cell line is a therapeutic cell line.

[0373] 96. A method for correcting cell behavior in cell culture experiments: (a) Conducting cell culture studies; and (b) The concentration of IGFBP2 used as a positive control in the cell culture study was detected according to the method of any one of embodiments 1 to 43.

[0374] 97. The method of implementation scheme 96, wherein the cell culture behaves normally if the IGFBP concentration is within the target range.

[0375] 98. The method of implementation scheme 97, wherein the target range is 50 ng / ml to 200 ng / ml.

[0376] 99. The method of any one of embodiments 96 to 98, wherein the cell culture experiment comprises culturing different cell lines under the same conditions.

[0377] 100. The method of embodiment 99, wherein the different cell lines comprise one or more test cell lines and one or more control cell lines.

[0378] 101. The method of embodiment 100, wherein the one or more control cell lines comprise a positive control cell line and / or a negative control cell line.

[0379] 102. The method of any one of embodiments 98 to 101, wherein the cell culture experiment comprises culturing the same cell line under different conditions.

[0380] 103. The method of any one of implementation schemes 99 to 102, wherein different cell lines are cultured simultaneously.

[0381] 104. The method of any one of embodiments 99 to 103, wherein for each cell culture in the experiment, the IGFBP2 concentration is detected according to the method of any one of embodiments 1 to 43.

[0382] 105. A method for determining the health of a test cell line, comprising: (a) The test cell line is seeded at a low density into a cell culture; and (b) The concentration of IGFBP2 in the test cell culture is detected according to any one of the embodiments 1 to 43.

[0383] 106. The method of implementation scheme 105, wherein the cell line is considered healthy if the IGFBP2 concentration is within the target range.

[0384] 107. The method of implementation scheme 105, wherein if the IGFBP2 concentration is below a target range, the cell line is considered to be over-merging.

[0385] 108. The method according to embodiment 106 or 107, wherein the target range is determined by: (a) Seeding one or more control cell lines at low density into a cell culture; and (b) The concentration of IGFBP2 in the control cell culture was detected according to any one of the methods in embodiments 1 to 43.

[0386] 109. The method of implementation scheme 108, wherein one or more control cell lines are seeded in parallel with the test cell line.

[0387] 110. The method of embodiment 108, wherein one or more control cell lines are seeded prior to the test cell line.

[0388] 111. The method of any one of embodiments 108 to 110, further comprising: detecting the IGFBP2 concentration in the control cell culture according to the method of any one of embodiments 1 to 43.

[0389] 112. The method of any one of embodiments 108 to 111, wherein the control cell line comprises a known healthy positive control cell line.

[0390] 113. The method of embodiment 112, wherein the test cell line is considered healthy if the IGFBP2 concentration in the test cell culture is at least 75% of the IGFBP2 concentration in the positive control cell culture.

[0391] 114. The method of any one of embodiments 108 to 113, wherein the control cell line comprises a negative control cell line known to be unhealthy.

[0392] 115. The method of embodiment 114, wherein the test cell line is considered healthy if the IGFBP2 concentration in the test cell culture exceeds the IGFBP2 concentration in the negative control cell culture.

[0393] 116. The method of any one of embodiments 106 to 115, wherein the target range is from 50 ng / ml to 200 ng / ml.

[0394] 117. The method of any one of embodiments 105 to 116, wherein the test cell line is a PSC.

[0395] 118. The method of implementation 117, wherein the PSC is preserved (e.g., cryopreserved).

[0396] 119. The method of implementation scheme 117 or implementation scheme 118, wherein the PSC is an iPSC.

[0397] 120. The method of embodiment 105, comprising: detecting a subsequent concentration of IGFBP2 and detecting a final concentration of IGFBP2 level, wherein if the final concentration of IGFBP2 level is lower than the subsequent concentration of IGFBP2 level, the cell line is considered to be over-merging.

[0398] 121. The method according to any one of embodiments 105 to 120, further comprising passage of cells in the cell culture (or the whole cell culture).

[0399] 122. The method of any one of embodiments 105 to 120, further comprising terminating the cell culture (e.g., by discarding or destroying the culture).

[0400] 123. The method of any one of embodiments 105 to 120, further comprising preserving cells in the cell culture (or the whole cell culture).

[0401] 124. The method according to any one of embodiments 105 to 120, further comprising destroying cells in the cell culture (or the entire cell culture).

[0402] 125. A method for testing cell culture parameters, such as for optimizing cell culture conditions, comprising: (a) Culture the cell line under the first set of parameters; (b) Culture the cell line under a second set of parameters that differ from at least one parameter of the first set of parameters; and (c) Detect the IGFBP2 concentration in (a) and (b) according to any one of the methods in Implementation Scheme 1 to 43.

[0403] 126. The method of Example 125, wherein the second set of parameters differs from the first set of parameters by only one parameter.

[0404] 127. The method of implementation scheme 125 or 126, further comprising determining whether the IGFBP2 concentrations detected in (a) and (b) are different.

[0405] 128. The method of any one of 125 to 127, wherein the IGFBP2 concentration detected in (a) is below the target range.

[0406] 129. The method of implementation scheme 128, wherein if the IGFBP2 concentration in (b) is within the target range, then the parameter is considered to have improved the health of the cell line.

[0407] 130. The method of implementation scheme 128, wherein if the IGFBP2 concentration in (b) is below the target range, then the parameter is considered not to improve the health of the cell line.

[0408] 131. The method according to any one of embodiments 125 to 130, wherein steps (a) and (b) are performed in parallel.

[0409] 132. The method of any one of implementations 125 to 130, wherein steps (a) and (b) are performed at separate times.

[0410] 133. The method of implementing 132, wherein step (a) is performed prior to step (b).

[0411] 134. The method of any one of embodiments 125 to 133, wherein one of the parameters is a culture medium.

[0412] 135. The method of any one of embodiments 125 to 133, wherein one of the parameters is a cell culture medium supplement.

[0413] 136. The method of any one of embodiments 125 to 133, wherein one of the parameters is a cell culture container coating parameter.

[0414] 137. The method of implementation scheme 136, wherein the cell culture container coating parameter is the type of coating matrix.

[0415] 138. The method of embodiment 136, wherein the cell culture container coating parameter is the duration of coating the cell culture container with a matrix.

[0416] 139. The method of embodiment 136, wherein the cell culture vessel coating parameter is the temperature at which the cell culture vessel is coated with a matrix.

[0417] 140. The method of any one of embodiments 125 to 133, wherein the cell culture parameter is the seeding density.

[0418] 141. The method of any one of embodiments 1 to 140, wherein the cell culture is a mammalian cell culture.

[0419] 142. The method of embodiment 141, wherein the mammalian cell culture is a human cell culture.

[0420] 8. Examples 8.1. Materials and Methods 8.1.1. Culture and maintenance of pluripotent stem cells (PSCs) Before culturing PSCs, culture vessels coated with the substrate should be kept at room temperature for at least two hours or overnight at 4°C. Cells suspended in Essential 8 (E8) medium supplemented with Y-27632 or CEPT mixture should be seeded at a preferred density (cells / cm²). 2 Spread the cells evenly on the culture surface. Incubate the culture containers overnight at 37°C in an incubator containing 5% CO2. On the second day and every day thereafter, until the cells reach 70% to 80% confluence, remove the culture containers from the incubator and observe the cells under a microscope. Drain the culture medium from each container compartment and replace it with fresh E8 medium without Y-27632, then return the culture containers to the incubator until use with trypsin-EDTA or Accutase. TM The standard method is to passage or prepare single-cell suspensions.

[0421] 8.1.2. PSC Subculture Experiment Procedure Remove the cell culture containers from the incubator and aspirate culture medium from each compartment. Wash the cells with PBS- / - and incubate with 0.5 mM EDTA in PBS at room temperature for 5 to 7 minutes. Rinse the culture surface of the containers with twice the volume of PBS containing EDTA in E8. Gently pipette up and down to preserve cell clumps, washing the culture surface no more than twice to separate any loosely attached cell colonies, and transfer the cell suspension to a tube. Wash the culture surface of the containers again with an additional volume of E8 and add the resulting cell suspension to the tube. Gently pipette the cell suspension in the tube up and down to ensure uniform cell distribution. Divide the appropriate volume of cell suspension at a 1:5 ratio into new centrifuge tubes and centrifuge at 300 g for 3 minutes. After removing the supernatant, loosen the cell pellet by tapping and / or shaking the tube and resuspend in an appropriate volume of E8 containing Y-27632 to obtain the preferred seeding density. Resuspended cells were seeded onto a substrate-coated container. After ensuring uniform cell distribution, the culture container was placed in an incubator set at 37°C and 5% CO2.

[0422] For Accutase TM Experimental procedure: Wash cells with PBS- / - and use Accutase at room temperature. TM Instead of 0.5 mM EDTA dissolved in PBS, incubate for 5 to 7 minutes. Rinse the culture surface of the container with twice the volume of PBS containing EDTA using E8. Gently pipette up and down to preserve cell clumps, washing the culture surface no more than twice to separate any loosely attached cell colonies, and transfer the cell suspension to a tube. Wash the culture surface of the container again with an additional volume of E8, and add the resulting cell suspension to the tube. Gently pipette the cell suspension in the tube up and down to ensure uniform cell distribution. Count the cells before proceeding to the next experimental step.

[0423] 8.1.3. Cell Counting Experiment Procedure 8.1.3.1. Cell counting based on Incucyte® Incucyte® Nuclight Rapid NIR dye was incubated at room temperature and diluted to 1:750 in complete culture medium. Used culture medium was withdrawn from the culture vessel, and cells in each compartment were washed with an equal volume of 1×HBSS. After adding an equal volume of dye-containing culture medium, the culture vessel was placed in the Incucyte® and allowed to equilibrate for 30 minutes. A standard scan was performed with phase and NIR selected. Cell counts were calculated by establishing an analytical protocol for counting NIR objects.

[0424] 8.1.3.2. Cell counting based on NC200 Sample at least 200 µL of homogenized single-cell suspension for analysis. Insert the tip of the Via-1 cartridge into the sample and press down the plunger to aspirate the sample, then insert the cartridge into the NC-200 (Chemometec, Denmark). From the main screen, select “Viability and Cell Count Assay.” Collect data related to percentage of viability, total cell count per mL, number of viable and non-viable cells, approximate cell diameter (in μm), and information on cell aggregation.

[0425] 8.1.3.3. Cell counting based on Cellometer K2 Mix 20 µL of homogenized single-cell suspension with 20 µL of AOPI solution. Transfer the 20 µL mixture to a disposable cell counting chamber and place the chamber in a Cellometer K2 (Nexcelom, MA, USA). In the setup screen, select the assay “hES cell AOPI” and the cell assay “hES cell AO”. Adjust the focus in preview mode if necessary. Collect data related to the percentage of viability, total cell count per mL, and the number of viable and non-viable cells.

[0426] 8.1.4. Enzyme-linked immunosorbent assay (ELISA) Using R&D Systems Quantakine TMELISA (R&D Systems, Catalog # DGB200; MN, USA) is used to detect IGFBP2 via enzyme-linked immunosorbent assay (ELISA) following the manufacturer's experimental procedures. In short, all reagents and samples are allowed to stand at room temperature before use. ELISA wash buffer is prepared by diluting 20 mL of concentrated wash buffer with 480 mL of deionized or distilled water (ddH2O). An IGFBP2 standard curve is prepared by reconstructing the standards with ddH2O using the volume listed on the vial label to produce a stock solution with a concentration of 200 ng / mL. After equilibration of the standard stock solution at room temperature for 15 minutes, a standard dilution is prepared by diluting 100 µL of the stock solution with 900 µL of Calibrator Diluent RD5-20, resulting in a maximum standard concentration of 20 mg / mL. Subsequent standards are prepared by serially diluting the remaining standards in two-fold increments to create an 8-point standard curve. After adding 100 µL of Assay Diluent to each well of a plate pre-coated with the captured antibody, add 50 µL of standard, control, or sample to each well as specified. Cover the plate with sealing film and incubate at room temperature for 2 hours. Aspirate and wash each well, repeating the process four times, and add 200 µL of conjugate to each well. Seal the plate and incubate at room temperature for 1 hour, aspirating and washing each well four times. Next, add 200 µL of substrate solution to each well and incubate the plate at room temperature in the dark for 30 minutes. Terminate the reaction by adding 50 µL of stop solution to each well. Place the plate in a reader and collect data at 450 nm over 30 minutes, with wavelength correction set to 540 nm or 570 nm. All samples, standards, and controls are tested repeatedly. Generate a standard curve to interpolate sample concentrations from absorbance values.

[0427] 8.1.5. Automated Immunoassay Follow the manufacturer's experimental procedures to perform IGFBP2 detection using the ELLA™ Automated Immunoassay System (ProteinSimple catalog #600-100). In short, scan the IGFBP2 cartridge barcode on the outside of the vacuum bag and remove the cartridge from the bag. Pipe 1 mL of wash buffer into the appropriate well and dilute the sample 1:10 with sample diluent. Pipe 50 µL of the diluted sample into the appropriate wells. Peel the protective liner from the bottom of the cartridge and load the cartridge into the ELLA system for detection.

[0428] 8.1.6. Homogeneous Time-Resolved Fluorescence (HTRF) Diluents were prepared using cell culture medium or PBS + 0.1% BSA. In short, a 12-point standard curve (std 0-std 11) was prepared by serially diluting the reconstituted stock solution by two-fold increases, with the highest standard concentration (std 11) at 1000 ng / mL, while std 0 was a protein-free negative control. 16 µL of standards were added to each well as specified. In the assay diluent, the receptor (D2) antibody was diluted to 5 µg / mL, and the donor (europium cryptate) antibody was diluted to 0.25 µg / mL, and the two antibody diluents were combined in a 1:1 ratio. 4 µL of the combined antibody mixture was added to each well, the plate was sealed, and incubated at 4°C for 4 hours. After incubation, the sealing membrane was removed, and time-resolved fluorescence was read on a CLARIOstar (BMG Labtech, Germany) or similar HTRF-compatible plate reader. All samples and standards were repeated three times. The ratio of acceptor to donor emission signals for each individual well was calculated using the following formula: Ratio = (665 nm signal) / (620 nm signal). A 4-Parameter Logistic curve was fitted to a standard ratio to interpolate the sample concentration.

[0429] 8.1.7. PSC differentiates into DA neurons Using the differentiation experimental procedures adapted from those described in Piao et al., 2021, Cell Stem Cell 28(2):217-229.e7, PCT Publications WO 2016,196661 A1, WO 2010 / 096496 A2, WO 2013 / 067362A1, WO 2021 / 042027 A1, WO2021 / 203009A1 and U.S. Patent No. 10,711,243, PSCs were differentiated into DA neurons at 16 days, all of which are incorporated herein by reference in their entirety.

[0430] 8.1.8. Three-dimensional amplification of PSC To generate 3D expanded PSCs, on day 0, PSC cell populations were seeded in Stemscale medium containing L-glutamine and medium containing 1× CEPT mixture or 10 μM Y-27632, and placed in an incubator set to 37°C and 5% CO2. The medium was replaced daily with Stemscale medium containing L-glutamine. On day 4, cells were isolated using EDTA using standard methods, resuspended in medium, and replate. The medium was replaced daily with Stemscale medium containing L-glutamine. On day 8, cells were isolated using standard methods utilizing Accutase™ and resuspended in medium to prepare starting PSCs for 3D culture. The starting PSCs were seeded into a suitable bioreactor (Eppendorf). Cells in the bioreactor were continuously perfused using an alternating tangential flow (ATF) perfusion apparatus to promote medium exchange and generate smaller aggregates.

[0431] 8.2. Example 1: IGFBP2 expression is closely related to seeding density and cell count. To determine whether there was a correlation between cell seeding density and IGFPB2 concentration in the supernatant, the IGFPB2 concentration in the supernatant collected from iPSC cultures seeded at various concentrations was assessed. Accutase was used. TM iPSCs were harvested and cell counts were determined using the NC200-based method described in Section 8.1.3.2. Cells were counted at concentrations of 25kJ, 50kJ, 100kJ, and 200kJ / cm³. 2 Cells were inoculated and placed in an incubator as described in Section 8.1.1. Supernatant was collected 24 hours after inoculation, culture medium was added to each compartment, and the cells were returned to the incubator. Supernatant was collected again after another 24 hours. IGFBP2 concentration was determined by ELISA using both sets of supernatant, following the method described in Section 8.1.4. The results of this assessment demonstrated a strong linear correlation between iPSC seeding density and IGFBP2 concentration at both 24 and 48 hours. Figure 2A ).

[0432] In the next evaluation, the relationship between cell count and IGFPB2 concentration in the supernatant will be assessed. Accutase will be used. TM Five distinct iPSC clones engineered to express IL12 were harvested and counted using an NC200 as described in Section 8.1.3.2. IGFBP2 in the supernatant was detected using HTRF as described in Section 8.1.6. The results of this assessment demonstrate a linear correlation between harvested cell counts and IGFBP2 concentration, where R0 2 =0.9591 ( Figure 2B ).

[0433] In summary, the results of these assessments provide evidence for the correlation between IGFBP2 and cell seeding density, as well as between IGFBP2 and cell count, suggesting that IGFBP2 can indicate the number of cells in a cell culture apparatus.

[0434] 8.3. Example 2: Comparison of experimental procedures for IGFBP2 expression and cell counting In this evaluation, IGFPB2 expression was compared with Incucyte® and NC200-based cell counting methods. Briefly, iPSCs were first counted using the NC200 as described in Section 8.1.3.2, and then at 13k, 25k, 50k, and 100k cells / cm². 2 Inoculate them. Over the next three days, collect the supernatant from the cells and change the culture medium as described in Section 8.1.1. Count the cells daily using the Incucyte® method as described in Section 8.1.3.1. On day 3, use Accutase... TM Harvest the cells and count them using the NC200-based method described in Section 8.1.3.2.

[0435] The concentrations of IGFBP2 in the supernatant samples at each inoculation density showed a linear correlation, although each group of experiments showed a different slope. Figure 3A The relationship is non-linear when IGFBP2 concentration is compared with Incucyte®-based cell counts. Figure 3B Because cell counts in the day 3 supernatant samples were assessed using both Incucyte® and NC-200-based methods, the day 3 IGFBP2 concentration was compared to these two cell counting methods. The results of this assessment showed a better linear relationship between NC200-based cell counts and IGFBP2 concentrations; however, the Incucyte®-based method underestimated cell counts. Figure 3C This may be because the Incucyte®-based method cannot accurately estimate cell counts when cells clump or aggregate.

[0436] 8.4. Example 3: Expression of IGFBP2 and cell number estimation in a cell factory Estimating cell numbers in a cell factory using visual methods, such as when estimating cell numbers in a culture dish without harvesting cells into a cell suspension, is challenging. Therefore, cell factories were used to evaluate the utility of IGFBP2 concentration for cell number estimation. In short, iPSCs grown in culture were passaged at approximately 4 million cells / layer into four 1-layer cell factories using EDTA. After 24 hours, the supernatant from one cell factory was collected. Accutase was used... TM Harvest cells from the cell factories and count them using a Cellometer K2 as described in Section 8.1.3.3. Replace the culture medium in the remaining three cell factories. Repeat this step three more times on days 2, 3, and 4. Perform IGFBP2 assay on the supernatant as described in Section 8.1.4.

[0437] The results of this assessment indicate that an increase in IGFBP2 over time is well correlated with an increase in NC200-based cell counts over time. Figure 4A and 4B This suggests that IGFBP2-based cell number estimation may be suitable for estimating cell numbers under visually challenging conditions, such as cell factories.

[0438] 8.5. Example 4: IGFBP2 expression and cell number estimation in clones producing secretory molecules. The applicability of IGFBP2-based cell number estimation to cells producing secretory molecules was evaluated. Briefly, iPSCs engineered to express the secretory molecule IL12 were passaged and treated with Accutase 24 hours after culture medium change. TM Supernatants were collected from 18 different iPSC clones. Cell counting was performed using the NC200-based method described in Section 8.1.3.2, and IL12 concentration in the supernatant samples was determined using a commercially available HTRF kit from Cisbio (CT, USA). IGFBP2 concentration was determined using the protocol described in Section 8.1.6.

[0439] Figure 5A The IL12 concentrations are shown as normalized to NC200-based cell counts. Figure 5B The figure shows IL12 concentration normalized to IGFBP2 concentration. The high similarity between the two figures suggests that IGFBP2 expression can be used to estimate the number of cells in clones that produce secretory molecules such as IL12.

[0440] 8.6. Example 5: IGFBP2 as a standardized marker for a single batch experiment In summary, engineered iPSCs expressing heterologous peptides were passaged, and supernatants were collected from 43 clones in 5 independent experiments 24 hours after culture medium replacement. Accutase was used as described in Section 8.1.3.2. TM Harvest cells and count them using an NC200. Detect IGFBP2 in the supernatant using the ELISA described in Section 8.1.4. Figure 6A The experiment showed the correlation between IGFBP2 concentration and [other factors]. Figure 6B The combined data of all experiments are shown, which demonstrates R. 2 The linearity of 0.85 indicates that IGFBP2 concentration can be used as a standardized biomarker across batch experiments.

[0441] 8.7. Example 6: IGFBP2 expression to assess cell health To assess whether IGFBP2 concentration measurements can be used to evaluate the health of cultured cells, IGFBP2 levels in healthy and unhealthy iPSCs can be evaluated. In an exemplary assessment, iPSCs can be cultured as described in Section 8.1.1. The iPSC culture containers can then be assigned to either a healthy control group or a treatment group designed to make the cells unhealthy. For example, different types of treatments (e.g., mechanical stress, chemical manipulation, suboptimal incubator conditions, etc.) or different levels of a single type of treatment (e.g., different concentrations of a chemical or different durations of chemical manipulation against the same chemical, resulting in varying levels of cell health) can be assessed by collecting supernatant samples from each treatment condition and comparing the absolute IGFBP2 concentration for each treatment condition, detected using an appropriate protocol (as described in Sections 8.1.4 and 8.1.6), with the IGFBP2 concentration in the supernatant sample from the untreated healthy control group.

[0442] 8.8. Example 7: Expression of IGFBP2 in PSC-differentiated DA neurons The utility of IGFBP2 concentration detection was evaluated in DA neurons differentiated from PSCs. Briefly, PSCs were maintained as described in Section 8.1.1, and cells were differentiated into DA neurons as described in Section 8.1.7. Supernatants from 11 different batches of cells were collected on days 12, 13, 14, 15, and 16 post-differentiation (D12–16). IGFBP2 was detected using Accutase as described in Section 8.1.5. TM Harvest the cells and calculate the cell count yield on D16 as described in Section 8.1.3.2.

[0443] The changes in IGFBP2 levels over time in DA neurons from different batches are shown in the figure. Figure 7A middle. Figure 7BThe study showed a correlation between IGFBP2 levels in DA neurons differentiated from 3D PSC cultures on day 12 (D12) post-differentiation and cell count yield on day 16 (D16), demonstrating R... 2 The linearity of 0.78 indicates that IGFBP2 concentration is suitable for estimating the number of cells differentiating from PSCs into DA neurons or cells that are differentiating into DA neurons.

[0444] 8.9. Example 8: Effects of coating conditions on IGFBP2 expression and cell count in cell factories IGFBP2 concentrations used for cell number estimation were assessed using cell factories subjected to different coating conditions. Briefly, iPSCs grown in culture were passaged into 12 separate 10-layer cell factories using EDTA, placed in matrix-coated containers, and incubated overnight at 4°C (cell factories 1–4) or coated for one hour at room temperature (cell factories 5–12). After 4 days, supernatants from each cell factory were collected and processed using Accutase. TM Harvest the cells and count them as described in Section 8.1.3.2. Perform IGFBP2 detection on the supernatant as described in Section 8.1.5.

[0445] Cell counts were lower in cell factories grown in containers coated with matrix for only one hour compared to cells grown in containers coated overnight. Figure 8A Similarly, the supernatant collected from cell factories grown in containers coated with the matrix for only one hour showed lower levels of IGFBP2 compared to those grown in containers coated overnight. Figure 8B IGFBP2 levels are well correlated with cell count. Figure 8C These results suggest that IGFBP2 reflects cell count differences related to culture conditions in multilayer cell factories and may be suitable for estimating cell numbers in visually challenging cell factories.

[0446] 8.10. Example 9: Effects of different supplements on IGFBP2 expression and globule formation in 3D PSC cultures.

[0447] To determine the effects of different supplements on IGFBP2 levels and globule formation, eight 3D PSC cultures were generated and maintained as described in Section 8.1.8, with four cultures using medium supplemented with a CEPT mixture and the remaining four using medium supplemented with Y-27632. Supernatants were collected, and the number of globules and total globule volume in each culture were assessed using FlowCam, where the samples were flowed through a flow cell, and images of the supernatants were rapidly captured using a 4× objective. Objects detected in the images were analyzed using FlowCam software, generating a report of over 40 morphological parameters for each object, including diameter. Total globule volume was estimated using the diameter of all objects greater than 50 µm. IGFBP2 in the supernatants was also detected as described in Section 8.1.5.

[0448] The IGFBP2 level in 3D PSC cultures supplemented with Y-27632 was lower than the IGFBP2 level in cultures supplemented with CEPT mixture. Figure 9A Similarly, the number of spheroids in 3D PSC cultures supplemented with Y-27632 was lower than the number of spheroids in cultures supplemented with CEPT mixture. Figure 9B Overall, IGFBP2 levels are associated with globular body counts ( Figure 10A ) and total spherical volume ( Figure 10B These results indicate that IGFBP2-based cell number estimation is applicable to estimating cell spheroid number and cell number in visually challenging 3D cell cultures.

[0449] 8.11. Example 10: Effects of seeding density on PSC cell count, IGFBP2 level, pluripotency markers, and confluence after replanting To further evaluate the relationship between cell seeding density, IGFPB2 concentration in the supernatant, total cell count, and cell density after replatening, PSC cultures seeded at various concentrations were assessed. Briefly, PSC cells from a single clone were passaged 1:10 and then passaged again to produce a total of six clones, one clone at a seeding density of 2.5 kb / cm². 2 Inoculation (clone 1), three clones at 5k cells / cm² 2 Inoculation (clones 2, 3, and 4), one clone at 10 kJ / cm² 2 Inoculate (clone 5) and one clone at 20 k cells / cm² 2Cells were seeded (clone 6) and placed in an incubator as described in Section 8.1.1. Supernatant was collected daily from all clones for four consecutive days. After supernatant collection, culture medium was replenished, and the cells were returned to the incubator. IGFBP2 concentration was determined using the supernatant as described in Section 8.1.5. Cells were collected from clones 1, 2, 5, and 6 on day 3 post-seeding, from clone 3 on day 4 post-seeding, and from clone 4 on day 5 post-seeding, as described in Section 8.1.2. Cell counts were assessed as described in Section 8.1.3.2. Pluripotency markers (NANOG, OCT4, SOX2, SSEA4) were assessed using FACS. Cells from each clone were counted at 50kJ, 100kJ, 200kJ, and 400kJ cells / cm³. 2 Re-plate the cells and assess cell confluence and recovery using an Incucyte live cell imaging system at 3 and 4 days after re-platening.

[0450] On day 1, IGFBP2 levels reflected the initial inoculation density under each condition ( Figure 11A Over four days, IGFBP2 levels increased in the supernatant of all clones, with the highest IGFBP2 levels (20 kb / cm²) associated with clone 6 on days 1–3. 2 The lowest IGFBP2 level was associated with clone 1 (2.5 kb / cm²). 2 () Figure 11B On day 4, the supernatant IGFBP2 level was at clone 5 (10k cells / cm²). 2 ) and clone 6 (20k cells / cm) 2 The two are comparable. Figure 11B ).

[0451] Cell count assessment of clone 2 on day 3, clone 3 on day 4, and clone 4 on day 5 (all clones at 5 k cells / cm²). 2 Inoculation showed a steady increase in cell number every day. Figure 11C A comparison of cell numbers at each seeding density condition on day 4 showed an increase in cell numbers within the clone, reflecting the seeding density of clones with lower seeding densities, which was not observed in over-confluent cells. Figure 11D ).

[0452] Cell confluence was assessed on days 3 and 4. On day 3, cells were counted at 2.5 kJ / cm². 2 and 5k cells / cm 2 Insufficient confluence of inoculated cells (respectively) Figure 12A and 12B ), at 10k cells / cm 2 The inoculated cells showed confluence within the optimal range. Figure 12C), and at 20k cells / cm 2 Over-confluence of inoculated cells ( Figure 12D On day 4, at 2.5 k cells / cm² 2 Insufficient confluence of inoculated cells ( Figure 12E ), at 5k cells / cm 2 The seeded cells showed confluence within the optimal range ( Figure 12F ), and at 10k cells / cm 2 and 20k cells / cm 2 Over-confluence of inoculated cells ( Figure 12G and 12H ).

[0453] During the evaluation, the expression of pluripotency markers was also affected by seeding density and clonal confluence. The percentage of cells expressing pluripotency markers under each condition is presented in Table 2 below and plotted on [the graph / plot]. Figures 13A-13D In 14A-14D. In short, it has 5k cells / cm 2 Increased confluence between clones at higher seeding densities led to a decrease in the percentage of cells positive for pluripotency markers (Table 2 and...). Figures 13A-13D Similarly, increased confluence among all clones assessed on day 4 resulted in a decrease in the percentage of cells positive for pluripotency markers (Table 2 and...). Figures 14A-14D The results of replate evaluation were also related to cell confluence, with over-confluenced clones showing lower confluence after replate formation. Figure 15A ) and recovery rate percentage ( Figure 15B It performed worse than other clones.

[0454] In summary, the results of these assessments provide a correlation between IGFBP2 levels and cell seeding density. Figure 16A ) and the correlation between IGFBP2 levels and cell counts on day 4 ( Figure 16B Evidence suggests that the percentage of IGFBP2 levels is correlated with cell confluence. Figure 16C and 16D The correlation between IGFBP2 levels and the pluripotency markers OCT4 and SOX2 is affected by confluence (respectively). Figure 16E and 16F (because there are no 20k cells / cm) 2 Reanalysis of the data led to a stronger correlation between the two biomarkers. Figure 16G and 16H These results indicate that IGFBP2 levels can indicate the number of cells in healthy cell cultures that are not excessively confluent.

[0455] 8.12. Example 11: Expression of IGFBP2 in cardiomyocytes differentiated from PSCs The utility of IGFBP2 concentration detection was evaluated in cardiomyocytes differentiated from PSCs. Supernatants from five different cardiomyocyte cultures were collected every other day from day 0 to day 34 of maturation. IGFBP2 was detected as described in Section 8.1.5.

[0456] The changes in IGFBP2 levels over time in each individual cardiomyocyte culture are shown in Figure 17A The culture conditions for cultures A, B, and C differed; for example, culture A was inoculated at a high seed density. The amounts of culture medium additives for cultures B (low) and B (high) differed. The pattern of increased IGFBP2 in culture B (low) cells indicated suboptimal maturity of these cells, as culture B cells with optimal levels of culture medium additives ( Figure 17B ) and cultures of B (low) cells with low levels of culture medium additives ( Figure 17C A comparison of FACS analysis showed that the latter had a higher level of impurities ( Figure 17B-17C (and Table 3). 9. Sequence List Exemplary sequences of this disclosure are provided in Table 4 below. 10. References All publications, patents, patent applications and other documents cited in this application are incorporated herein by reference in their entirety for all purposes, as if each individual publication, patent, patent application or other document were individually indicated as being incorporated herein by reference for all purposes. In the event of any inconsistency between the teachings of one or more of the references incorporated herein and the contents of this disclosure, the teachings of this specification shall prevail.

Claims

1. A method comprising: (a) Detecting the initial concentration of insulin-like growth factor binding protein 2 (IGFBP2) in the culture medium of cell cultures ("Initial Detection Step"); (b) Optionally, detect at least one subsequent concentration of IGFBP2 in the culture medium of the cell culture (each "subsequent detection step"); and (c) Optionally, the final concentration of IGFBP2 level in the culture medium of the cell culture is detected ("final detection step").

2. The method of claim 1, further comprising step (b).

3. The method of claim 2, wherein step (b) includes detecting multiple subsequent concentrations of IGFBP2 in the culture medium of the cell culture.

4. The method of claim 3, wherein step (b) is repeated once or twice a day for at least three days.

5. The method of claim 4, wherein step (b) is repeated daily until one or two days before the cell culture is passaged.

6. The method according to any one of claims 3 to 5, wherein step (b) is repeated every other day for at least 6 days.

7. The method according to any one of claims 1 to 6, wherein each subsequent detection step is performed when the cell culture is not fed.

8. The method according to any one of claims 1 to 7, wherein the concentration of IGFBP2 in the culture medium indicates the number of cells in the cell culture.

9. The method according to any one of claims 1 to 7, wherein the concentration of IGFBP2 in the culture medium indicates the maturity of cells in the cell culture.

10. The method according to any one of claims 1 to 9, further comprising feeding the cell culture after one or more subsequent detection steps.

11. The method of claim 10, wherein the cell culture is fed daily.

12. The method according to any one of claims 1 to 11, further comprising step (c).

13. The method of claim 12, wherein the final detection step is performed when the cell culture is not replenished.

14. The method according to any one of claims 1 to 13, wherein one or more (or all) of an initial detection step, one or more subsequent detection steps (if performed) and / or a final detection step (if performed) are performed such that the detection indicates the number of cells in the cell culture.

15. The method according to any one of claims 1 to 14, wherein at least 12 hours have passed since the previous feeding, one or more (or all) of the initial detection step, one or more subsequent detection steps (if performed), and / or the final detection step (if performed) are performed.

16. The method according to any one of claims 1 to 15, comprising step (c) and further comprising step (d), wherein step (d) comprises any combination of one, two, three, or all four of the following steps: (i) Disrupt the cells in the cell culture (or the entire cell culture); (ii) Passage the cells in the cell culture (or the whole cell culture); (iii) Preserving cells from the cell culture (or the whole cell culture); and (iv) If the cell culture contains pluripotent stem cells (PSCs), then differentiate the PSCs in the PSC cell culture (or the entire PSC cell culture).

17. The method of claim 16, wherein step (d) comprises: If the final concentration of IGFBP2 in the cell culture medium is (a) below the threshold amount and / or (b) outside the target range, the cell culture is destroyed.

18. The method of claim 16, wherein step (d) comprises: If the final concentration of IGFBP2 in the cell culture medium (a) is above the threshold amount and / or (b) is within the target range, then the cells in the cell culture (or the whole cell culture) are passaged.

19. The method of claim 16 or 18, wherein step (d) comprises: If the final concentration of IGFBP2 in the cell culture medium is (a) higher than the threshold amount and / or (b) within the target range, then cells from the cell culture (or the whole cell culture) are preserved.

20. The method of claim 16, wherein step (d) comprises: If the final concentration of IGFBP2 in the cell culture medium (a) is higher than the threshold amount and / or (b) is outside the target range, the cell culture is destroyed.

21. The method of claim 16, wherein step (d) comprises: If the final concentration of IGFBP2 in the cell culture medium is (a) below a threshold amount and / or (b) within the target range, then cells from the cell culture (or the whole cell culture) are preserved.

22. The method according to any one of claims 17 to 19, wherein the target range is from 50 ng / ml to 200 ng / ml.

23. The method according to any one of claims 1 to 22, wherein the detection step is performed via an immunoassay, optionally wherein the immunoassay is an enzyme-linked immunosorbent assay (ELISA), a fluorescence resonance energy transfer (FRET) assay, or a Western blot.

24. The method according to any one of claims 1 to 23, wherein the cell culture is an adherent culture.

25. The method according to any one of claims 1 to 23, wherein the cell culture is a suspension.

26. The method according to any one of claims 1 to 23, wherein the cell culture is a three-dimensional (3D) cell culture.

27. The method according to any one of claims 1 to 26, further comprising forming the cell culture prior to step (a).

28. The method according to any one of claims 1 to 27, wherein the cell culture comprises PSCs and / or cells that have undergone differentiation from PSCs into another cell type.

29. The method of claim 28, wherein the cell culture is seeded with a preserved (e.g., cryopreserved) population of PSC cells.

30. The method according to any one of claims 27 to 29, wherein the PSC is an iPSC.

31. The method of claim 30, wherein the iPSC is the product of a process comprising: (a) Dedifferentiated somatic cells; (b) Introducing one or more nucleic acids encoding the mountain factor into the adult cells; and (c) The adult cells are cultured under conditions expressing the Yamanaka factor to generate a population of iPSCs.

32. The method according to any one of claims 28 to 31, wherein step (d) (if present) comprises: If the final concentration of IGFBP2 in the cell culture medium (a) is above the threshold amount and / or (b) is within the target range, then PSCs are differentiated from the PSC cell culture.

33. The method of claim 32, wherein the target range is from 50 ng / ml to 200 ng / ml.

34. The method according to any one of claims 28 to 33, further comprising detecting an additional concentration of IGFBP2 level in the culture medium of the cell culture before, during, or after the differentiation of PSCs from the PSC cell culture.

35. The method according to any one of claims 32 to 34, wherein the PSCs from the PSC cell culture differentiate into dopaminergic neurons.

36. The method according to any one of claims 32 to 35, further comprising repeating the method according to any one of claims 1 to 27 during and / or after differentiation.

37. The method according to any one of claims 1 to 36, wherein the cell culture comprises dopaminergic neurons.

38. The method according to any one of claims 1 to 27, wherein the cell culture comprises cells that have undergone maturation (e.g., cardiomyocytes).

39. A method for identifying cell lines suitable for producing secretory polypeptides, comprising: (a) Detecting the IGFBP2 concentration in cell cultures of the cell line according to any one of claims 1 to 27; (b) While detecting IGFBP2, the concentration of secreted peptides in the cell culture was also detected.

40. A method for correcting cell activity in cell culture experiments: (a) Conducting cell culture studies; and (b) The concentration of IGFBP2 used as a positive control in the cell culture study was detected by the method of any one of claims 1 to 27.

41. A method for determining the health of a test cell line, comprising: (a) The test cell line is seeded into a cell culture at a low density; and (b) Detecting the IGFBP2 concentration in the test cell culture according to any one of claims 1 to 27.

42. A method for testing cell culture parameters, comprising: (a) Culture the cell line under the first set of parameters; (b) The cell line is cultured under a second set of parameters that differ from at least one parameter of the first set of parameters; and (c) Detecting the IGFBP2 concentration in (a) and (b) by any one of claims 1 to 27.

Citation Information

Patent Citations

  • Micro-plate reader for elisa testing

    EP3311163B1

  • Biomarker for barrett's oesophagus

    US10551392B2

  • Midbrain dopamine (DA) neurons for engraftment

    US10711243B2

  • Method of treating psoriatic arthritis with increased interval dosing of anti-IL12 / 23 antibody

    US11197913B2

  • Nuclear reprogramming factor and induced pluripotent stem cells

    US20090047263A1